ANNUAL REPORT 2019
GENERATIONS OF IMPACT
LEUKEMIA & LYMPHOMA SOCIETY
GENERATIONS OF IMPACT
The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.
Table of Contents

CELEBRATING 70 YEARS 2
SPOTLIGHTING OUR IMPACT 4
ADVANCING OUR MISSION IN 2019 6
TAKING ON CHILDREN’S CANCER FROM EVERY DIRECTION 8
ACCELERATING CURES 14
DRIVING CLINICAL TRIAL INNOVATION, EDUCATION AND ENROLLMENT 18
HELPING PATIENTS THROUGHOUT THEIR CANCER EXPERIENCE 22
BREAKING DOWN BARRIERS TO CARE 26
DRIVING SUPPORT ACROSS THE COUNTRY 30
PARTNERING FOR PROGRESS TOWARD CURES 32
RECOGNIZING OUR SUPPORTERS 34
ACKNOWLEDGING OUR EXTRAORDINARY VOLUNTEERS 36
FINANCIALS 38
ACKNOWLEDGMENTS 57

Please visit www.LLS.org/AnnualReport to read our full Fiscal Year 2019 Annual Report, including financials and acknowledgments.
Dear Friends,

You are part of our story—the story of The Leukemia & Lymphoma Society (LLS)—which begins with one family’s hope and will end with curing cancer in our lifetime.

Rudolph and Antoinette Roesler de Villiers founded LLS in 1949 after losing their 16-year-old son Robbie to leukemia. Determined to spare other families the devastating loss of a child, the de Villiers set out to transform cancer treatment and care. As an organization founded by a family for families, our vision is rooted firmly in the de Villiers’ relentless drive to create a world without blood cancer.

Since our founding, generations of patients, survivors, caregivers, families, volunteers, researchers, healthcare professionals and supporters have joined our quest for cancer cures. In 2019, LLS celebrated our 70th anniversary by looking to inspiration of the past to propel us forward. To mark the occasion, we invited our global community to help us grow a digital family tree on www.LLS.org by sharing stories of impact.

Stories like that of Dr. James Holland, who was a trailblazing researcher. In 1955, LLS awarded a grant to Dr. Holland, whose discovery helped establish the first standard of care for children with leukemia. Today, this story resonates even more in light of our recent launch of The LLS Children’s Initiative, a $100 million comprehensive endeavor to deliver cures and better care to children with cancer.

Here at LLS, beating cancer is in our blood. Over the past 70 years, we have invested nearly $1.3 billion in cutting edge research worldwide, fueling virtually every critical advancement in blood cancer treatment, including pioneering chimeric antigen receptor (CAR) T-cell immunotherapies that supercharge patients’ own immune cells to attack cancer. Many of these groundbreaking treatment approaches, first discovered in blood cancer, are now being tested in clinical trials for other cancers and diseases, such as breast, lung, pancreatic and prostate cancer.

We believe there is no one way to beat cancer. The future of cancer treatment hinges on giving the right treatment to the right patient at the right time. LLS is bringing the promise of precision medicine and immunotherapy to more patients in urgent need across every aspect of our mission work.

At the same time, we are relentless about helping patients, caregivers and families throughout their entire cancer experience to ensure they have access to care. LLS is the leading source of free blood cancer information, education and support for patients, survivors, caregivers, families and healthcare professionals. And through our nationwide
grassroots network of more than 50,000 active online volunteers, we drive lifesaving policies that accelerate the development of new cancer treatments and break down barriers to care.

While we’ve made incredible progress, blood cancers are the second leading cause of cancer deaths in the U.S.—a sobering reminder that we have more work to do. We need to change fundamentally how children with cancer are treated. We need to advance new and efficient clinical trial models to deliver more breakthroughs, and importantly, we need to help patients access these trials. And we need to take bold action for patients against the staggering cost of cancer care.

Every facet of our mission is working in harmony to put patients first and address these priorities. As a global leader in the fight to end cancer, with your support, we press on with unwavering dedication.

Gratefully,

— Rudolph Roesler de Villiers

“Everyone is supposed to fulfill a certain purpose in life; Robbie’s seems to have been to make others happy with his joyful, inspiring nature, his wit and knowledge, and as young as he was—in fact hardly more than a child—to earn the right not to be forgotten.”

— Rudolph Roesler de Villiers
SPOTLIGHTING OUR IMPACT

Our work has helped millions impacted by cancer.

Since the 1960s, survival rates for many blood cancer patients have doubled, tripled or even quadrupled. What’s more, we’ve seen an average decline of 32 percent in blood cancer death rates since the 1990s. That’s the power of the LLS mission. By funding pioneering cancer research to advance treatments and cures and helping patients and families access the care they need, we are saving and improving the lives of patients and giving hope to countless families across the globe. But we won’t stop until we achieve a world without blood cancer.

“Thanks to LLS, a new treatment was available each time I relapsed, and those new treatments provided hope for my family and me.”

— Peter Pearson, a three-time cancer survivor first diagnosed with Hodgkin lymphoma in 2013

Peter participated in a clinical trial for a targeted therapy called brentuximab vedotin (Adcetris®), which LLS-funded research helped advance. In 2018, the FDA approved this therapy in combination with chemotherapy to treat newly diagnosed patients with advanced Hodgkin lymphoma, representing the first change in the standard of care for the disease in 40 years. Today, Peter and his family raise funds for LLS through Big Climb, Light The Night and Pennies for Patients.
Since the 1960s, survival rates for many blood cancer patients have doubled, tripled or even quadrupled.

We’ve seen an average decline of 32 percent in blood cancer death rates since the 1990s.

NEARLY
$1.3B
INVESTED IN BLOOD CANCER RESEARCH WORLDWIDE SINCE 1949

LEADING SOURCE
OF FREE EDUCATION AND SUPPORT FOR BLOOD CANCER PATIENTS AND FAMILIES

MORE THAN
50,000
ACTIVE ONLINE VOLUNTEERS ADVOCATE FOR LIFESAVING POLICIES
ADVANCING OUR MISSION IN 2019

Thanks to you, our 70th year was the most impactful one yet at LLS.

LLS HELPED ADVANCE
46 OF THE 53
BLOOD CANCER TREATMENT OPTIONS
APPROVED BY THE U.S. FOOD AND
DRUG ADMINISTRATION (FDA)
SINCE 2017.

IN ADDITION TO OUR BEAT AML MASTER
CLINICAL TRIAL, LLS SUPPORTED
MORE THAN 240
CUTTING EDGE RESEARCH GRANTS AND
22
THERAPY ACCELERATION PROGRAM (TAP)
PARTNERSHIPS WORLDWIDE.

LLS HAS SEEN PROGRESS ON
75 PERCENT
OF THE 31 POLICY RECOMMENDATIONS
WE PUT FORTH TO CONGRESS,
AIMED AT LOWERING THE COST OF
CANCER CARE FOR PATIENTS WHILE
PROTECTING ACCESS TO QUALITY CARE.

LLS VOLUNTEER ADVOCATES SENT
MORE THAN 8,400
LETTERS IN SUPPORT OF THE CANCER
DRUG PARITY ACT, INTRODUCED TO CONGRESS
TO ENSURE ACCESS TO ALL CANCER
TREATMENTS, REGARDLESS OF HOW
TREATMENTS ARE ADMINISTERED.

WHAT’S THE LATEST IN
BLOOD CANCER RESEARCH?

Lee Greenberger, PhD, Chief Scientific Officer at LLS,
shares what key trends mean for patients.

1. **The genomics revolution is here.** Blood cancers—which consist of more than 100 different types of diseases—are complex, but we’re cracking the code, thanks to new genomic technologies. Equipped with powerful molecular methods and a deeper understanding of our genetic blueprint, we’re learning more about what causes blood cancer and why certain therapies work and why some fail.
Your support helped LLS invest $283.9 MILLION in our mission this year, bolstering research, education and support, and policy and advocacy efforts that helped put patients and their families first.

**LLS INFORMATION SPECIALISTS RESPONDED TO MORE THAN 20,000 INQUIRIES FROM PATIENTS AND CAREGIVERS IN 2019 ALONE.**

**LLS CLINICAL TRIAL NURSE NAVIGATORS PROVIDED MORE THAN 600 PATIENTS WITH IN-DEPTH CLINICAL TRIAL NAVIGATION AND SUPPORT.**

**THIS YEAR, OUR LIGHT THE NIGHT, MAN & WOMAN OF THE YEAR AND STUDENTS OF THE YEAR CAMPAIGNS BROKE FUNDRAISING RECORDS AS DEDICATED PARTICIPANTS DROVE MORE SUPPORT FOR OUR MISSION THAN EVER BEFORE.**

**THANKS TO OUR INCREDIBLE SUPPORTERS, WE ACHIEVED OUR $125 MILLION FUNDRAISING GOAL FOR OUR COMPREHENSIVE EFFORTS TO BEAT ACUTE MYELOID LEUKEMIA (AML).**

2. **Precision medicine is on the rise.** Chemotherapies destroy cancer cells, but also damage normal cells, causing substantial side effects. Today, more recently approved oral targeted therapies attack blood cancer cells specifically, while sparing healthy cells with impressive results. For example, the FDA-approved combination of venetoclax (Venclexta®) and obinutuzumab (Gazyva®) marks a new chemotherapy-free, front-line treatment for chronic lymphocytic leukemia. LLS has supported research advancing venetoclax for the past 15 years. Venetoclax, when used in combination with conventional chemotherapy, is also a game changer for AML.

3. **The golden age of immunotherapy continues.** LLS is advancing different approaches that activate the immune system to fight cancer, including CAR T-cell immunotherapies and cancer vaccines. We’re exploring every avenue to improve CAR T-cell therapy so that more patients with blood cancer achieve long-lasting disease control.

4. **Prevention is the new frontier.** Advances in genomics are allowing us to identify individuals who are at a higher risk of developing blood cancer years before it might occur with the use of a blood test. Researchers are also exploring how to prevent early precursor diseases from progressing to more serious blood cancers.
"I stand in defiance against childhood cancer. Losing my son Zach was unimaginably devastating, but his struggle makes me all the more relentless about accelerating better treatments and care, so we can save the lives of more children and spare others from life-altering, long-term side effects."

— Julie Guillot, Volunteer Chair, Pediatric Partnerships and Outreach at LLS

**BY THE NUMBERS**

**APPROXIMATELY 80%**

OF CHILDHOOD CANCER SURVIVORS DEVELOP ONE OR MORE CHRONIC HEALTH CONDITIONS AS A RESULT OF TREATMENT

**IN THE LAST 40 YEARS, ONLY 4 ONCOLOGY DRUGS**

HAVE BEEN APPROVED FOR FIRST USE IN CHILDREN
Taking on Children’s Cancer from Every Direction

Fighting for Children with Cancer

Julie Guillot never imagined the harrowing struggle that would follow after her eldest son, Zach, was diagnosed with acute myeloid leukemia (AML) at the age of 5. For four years, Zach endured brutal chemotherapy, radiation, fevers, unyielding nausea and months confined to three different hospitals. A fan of superheroes, he faced the daunting regimen with bravery. But the intensity of his treatments took a tremendous toll. Sadly, Zach passed away after his third bone marrow transplant. “I won’t stop fighting for Zach. I am determined to do as much as I can so other families don’t have to go down this terrible path,” says Julie. Today, Julie is an influential parent advocate and LLS volunteer who is dedicated to speeding safer, more curative therapies for children.

Delivering Cures and Better Care

For many childhood cancers, chemotherapies developed decades ago remain the standard of care and simply don’t work well enough. Too many children succumb to their cancer. Survival rates for high-risk forms of blood cancer, such as AML, are especially poor. For those who do survive, the long-term effects of treatment can cause life-threatening complications and secondary illnesses and cancers.

LLS is disrupting the status quo with our bold vision: we want children not only to survive cancer, but thrive in their lives after treatment. That’s why we launched The LLS Children’s Initiative: Cures and Care for Children with Cancer, a full-scale, multi-year endeavor to take on children’s cancer from every direction.

“Every young life lost to cancer is one too many. We must do better. With The LLS Children’s Initiative, we will,” says Gwen Nichols, MD, LLS Chief Medical Officer.

ABOUT 40% OF PEDIATRIC CANCERS ARE BLOOD CANCERS
Taking on Children’s Cancer from Every Direction (cont.)

Overcoming Obstacles to Progress

For too long, children have been treated with a one-size-fits-all approach, despite cancer behaving differently in children than in adults. “Children are not little adults; they need therapies that are designed just for them,” says Dr. Nichols. But given the relatively small patient population, there has not been enough incentive for the private sector to pursue pediatric drug development.

Beyond research, there are regulatory hurdles and access issues, including financial and geographic barriers, which stand between patients and the care they need.

Only LLS has the proven track record, leadership and visionary supporters needed to usher in a new era of pediatric cancer treatment and care.

Our goal is to revolutionize the standard of care for children with cancer, providing them with safer, more effective treatments that rely less on chemotherapies that harm healthy cells in the body.

“When a child is diagnosed with cancer, it affects the entire family. The support we received from the two LLS programs helped us focus on taking care of King and made us feel less alone in our journey. King has been dealing with cancer for most of his young life, and has a long road ahead of him still. But we are hopeful that with LLS leading the charge, more children will survive cancer and thrive in their lives after treatment.”

— Shameeza Singh, King’s mother

King was diagnosed with high-risk acute lymphoblastic leukemia (ALL) in June 2016 at the age of 2. His treatment plan included three and a half years of daily chemotherapy. He took 75 pills per month, in addition to intravenous and spinal chemotherapy. During this time, he experienced severe complications, including brain swelling, nerve damage, painful mouth sores and more. His family received support from LLS through our Urgent Need Program and Patient Aid Program. In October 2019, King completed chemotherapy, but continues to battle the chronic side effects from his treatment and a lifelong genetic disorder called G6PD deficiency. King and his family spend their time advocating and spreading awareness about pediatric cancer.
Austin has been cancer free for six years, thanks to an LLS-supported CAR T-cell immunotherapy.
Taking on Children’s Cancer from Every Direction (cont.)

The LLS Children’s Initiative will bring precision medicine to children with cancer and ensure they have access to care.

Driving New Breakthroughs Faster

LLS is more than doubling our investment in pediatric cancer research grants worldwide. Our areas of focus include:

• Harnessing the immune system to fight cancer
• Identifying biomarkers to understand which patients will respond to certain therapies
• Overcoming treatment resistance
• Improving detection of cancer cells left after treatment that can lead to relapse
• Mitigating long-term treatment effects, such as cardiotoxicity and infertility

Further, LLS has undertaken an unprecedented collaboration to launch the first global precision medicine clinical trial for pediatric acute leukemia, called LLS PedAL. Building upon our successful Beat AML® Master Clinical Trial, LLS will unite physicians, scientists, regulators, advocacy organizations, pharmaceutical and biotechnology companies and others to change the paradigm of treatment through a precision medicine approach that puts pediatric patients first. Together, we will create a single set of pediatric cancer data that will be made available to researchers worldwide, identify and validate underlying molecular drivers of disease, and match patients with relapsed acute leukemia to the most promising treatments based on their unique tumor biology. The goal is to test multiple targeted therapies simultaneously at up to 200 clinical sites worldwide, with an anticipated opening in 2020.

Ensuring Access to the Best Care Possible

Because new breakthroughs are beneficial only if patients can access them, we are expanding our trusted education and support services—including resources for children and young adults with cancer and financial assistance programs—to help more patients, parents and caregivers navigate cancer treatments and access quality care. LLS is dedicated to helping children and families cope with the financial, emotional and psychological impact of a cancer diagnosis through our comprehensive array of free information, education and support.

Meanwhile, our policy and advocacy efforts focus on breaking down barriers to care and accelerating the development of new cancer treatments. LLS is co-chairing the Policy Committee of the Alliance for Childhood Cancer, a coalition of more than 25 advocacy groups and professional organizations. Through our work with the coalition, we played an instrumental role in the enactment of The Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act, the most comprehensive federal childhood cancer legislation ever introduced.
Myrrah, leukemia survivor
“I was inspired by past LLS Career Development Program awardees, many of whom are now leaders in the field. This award from LLS provides a tremendous boost to our research.”

— G. Greg Wang, PhD, University of North Carolina Lineberger Comprehensive Cancer Center

Dr. Wang is using a cutting edge gene-editing tool called CRISPR, combined with genetic profiling, to understand how a particular mutation called DNMT3A leads to the development of AML. With these insights, researchers can develop innovative new treatment strategies.
Accelerating Cures

Leading the Way to Cures

Our growing understanding of the genetic underpinnings of blood cancer is breaking new ground in cancer treatment and care. By supporting the full spectrum of research, from basic, laboratory-based science to large-scale clinical trials, LLS is at the forefront of the fight to cure cancer. At the same time, we’re working tirelessly to ensure that treatment advances reach blood cancer patients. LLS is redoubling efforts to connect patients to clinical trials, which are critical avenues to improving access to care and discovering breakthroughs. Further, our Office of Public Policy works to increase research funding at the National Institutes of Health (NIH) and other federal agencies, accelerate FDA approval processes while still protecting patient safety, and promote patient-focused drug development that prioritizes patients’ needs and concerns.

Investing in Pioneering Research

LLS is the largest nonprofit funder of blood cancer research. In 2019, we dedicated $47.4 million to support scientific grants, including 106 new grants awarded to researchers across the globe. With more than 35 new Career Development Program grants, we continue to bolster the early careers of scientists. Our support of promising young scientists has produced three Nobel Prize winners, more than 15 National Academy of Sciences members and more than 10 department chairs of major cancer centers.

LLS invested $7 million of our 2019 research budget in our Therapy Acceleration Program® (TAP), a venture philanthropy model through which we partner with biotech and academic institutions to advance promising novel therapies. New TAP partners include industry leaders such as Forty Seven, Inc., Sutro Biopharma, X4 Pharmaceuticals, Inc. and Verastem Oncology. Since 2017, three TAP-supported treatments were approved by the FDA.

Collaborating for Cures

LLS is driving innovative multi-year partnerships to maximize our research investment, including:

- A $1.8 million partnership with the Snowdome Foundation and Australia’s Leukaemia Foundation to support leading blood cancer research projects in Australia

- A $6.75 million collaboration between LLS, The Mark Foundation for Cancer Research and The Paul G. Allen Frontiers Group to boost critical discovery research by seasoned investigators

- A $4 million partnership with the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) to accelerate global immunotherapy and prevention research

- A $1.5 million partnership with the RUNX1 Foundation to advance better treatments for RUNX1 familial platelet disorder
Championing Immunotherapy

Our more than 20-year investment in CAR T-cell immunotherapy has paid off with two approved treatments for children and young adults with acute lymphoblastic leukemia (ALL) and adults with certain highly lethal lymphomas who have exhausted all other treatment options. Remarkably, many patients remain free of disease years after a single CAR T-cell dose. Today, we are funding the next generation of this game changing approach:

• **Helen Heslop, MD, Baylor College of Medicine,** is driving new immunotherapies for leukemia, lymphoma and myeloma. Her visionary team is maximizing approved CAR T-cell immunotherapies and developing “off the shelf” CAR-Ts that use cells from donors instead of patients to reduce production time.

• **Jianhua Yu, PhD, City of Hope,** is combining CAR-T and bispecific antibodies, two living drugs that launch persistent immune responses against cancer cells, to treat myeloma.

Based on the success in blood cancer, researchers are investigating applications in solid tumors, including lung, breast, colon and prostate cancer.

Outsmarting Cancer with Precision Medicine

LLS is unifying goals among science, industry, cancer centers, regulators, philanthropists and patients to revolutionize cancer treatment through precision medicine. Our Beat AML Master Clinical Trial is a case in point. Launched in 2016, the Beat AML Master Clinical Trial is the first collaborative precision medicine clinical trial in a blood cancer. The trial uses advanced genomic technology to identify each AML patient’s cancer-driving genetic mutations, and then matches patients to the most promising targeted treatment within a rapid timeframe. More than 760 patients have been screened in 11 study arms at 16 cancer centers across the country.

Other highlights include:

• **Robert Orlowski, MD, PhD, University of Texas MD Anderson Cancer Center,** and his colleagues are studying the unique molecular features of patients with myeloma precursor diseases, so treatment can be tailored to prevent progression to full-blown myeloma.

• **Ari Melnick, MD, Weill Cornell Medicine,** is advancing novel therapies for B-cell lymphomas that target specific epigenetic mechanisms, the switches that turn genes on or off and control cell behavior.

• **Craig Jordan, PhD, University of Colorado,** is leading a world-class team of researchers to eradicate cancer stem cells—the roots of disease—in patients with AML through personalized approaches. This work is supported by a matching fund from the University of Colorado Medical Center.
“LLS’s early and sustained research investment in CAR T-cell immunotherapy is the reason I am here today and able to cherish every moment with my daughter.”

— Chuck Colletti, diagnosed with non-Hodgkin lymphoma in 2016

This year, Chuck fundraised proudly for LLS through our Man & Woman of the Year campaign.
Driving Clinical Trial Innovation, Education and Enrollment

Understanding the Value of Clinical Trials

Without sufficient enrollment in clinical trials, new treatments cannot be approved, scientific knowledge stalls and patients cannot access potentially lifesaving therapies. But the landscape is complex and evolving rapidly. Patients and caregivers are often left to search for trials on their own, leaving them with more questions than answers. The process can be cumbersome for healthcare professionals, too. Clinical research in the era of precision medicine is homing in on smaller groups of patients with specific disease subtypes or characteristics. Too many trials fail to meet their goals because there are not enough patients enrolled. Clinical trials are not “last resort” options, but rather avenues to leading edge care. LLS is committed to connecting patients to clinical trials, funding groundbreaking clinical science and advocating for policies that put patients at the center of their care.

Improving Access and Participation

LLS continues to expand our Clinical Trial Support Center (CTSC), in which Clinical Trial Nurse Navigators—registered nurses with expertise in blood cancers—conduct comprehensive clinical trial searches and assist patients and caregivers throughout the entire clinical trial enrollment process. Together, LLS Clinical Trial Nurse Navigators and LLS Information Specialists—master’s level oncology professionals—work one-on-one with blood cancer patients and caregivers to help them become more active participants in their care and overcome barriers to enrolling in trials, including assistance with finances and lodging.

On average, it takes more than 30 interactions with a patient, their caregivers and healthcare professionals to help a patient enroll in a clinical trial. This year, LLS Clinical Trial Nurse Navigators had nearly 8,000 interactions with patients, caregivers and healthcare professionals, demonstrating the depth and breadth of our support.

With only about 5 percent of all adult cancer patients in the U.S. enrolling in clinical trials, LLS is helping to bridge this enrollment gap with our free, personalized clinical trial navigation for blood cancer patients and their families. Typically, 22 percent of patients who are assisted by the CTSC enroll in an appropriate clinical trial, showing the power of our in-depth support on the lives of patients.
I was on a mission to stay alive. The treatment options at the time were few, lacked effectiveness and had difficult side effects. After enduring six different treatments over 12 years, I achieved a complete remission finally, thanks to a clinical trial for an LLS-supported CAR T-cell immunotherapy.

— Laurie Adami, diagnosed with non-Hodgkin lymphoma in 2006

She has set the goal of participating in Team In Training’s Climb 2 Cure at Mount Everest Base Camp in spring 2020.

LLS offers a wide array of free education and support for patients, caregivers and healthcare professionals.

- LLS Clinical Trial Nurse Navigators
- LLS Information Specialists
- Weekly online chats
- Peer-to-peer support
- Online social network called LLS Patient Community
- Financial assistance
- Nutrition consultations
- Caregiver support
- Webcasts
- Videos
- Podcasts
- Information booklets
- Continuing Education/Continuing Medical Education programs
Looking Forward

Beginning in 2020, LLS will expand a dynamic collaboration with the American Society of Hematology (ASH) to provide more than 2,500 ASH member physicians in the U.S. and Canada with dedicated access to the CTSC, making it easier to refer patients to our personalized support. This collaboration builds upon a successful pilot program completed in 2018, which found that the CTSC helped physicians have informed discussions with their patients about clinical trials as a possible course of treatment.

LLS is also working to expand clinical trial access among blood cancer patients in underserved communities. Through our new research program, Impactful Medicine Providing Access to Clinical Trials (IMPACT), we aim to bring innovative clinical trials to patients served by community cancer centers, especially in rural or economically disadvantaged areas. By fostering partnerships between community-based oncologists and clinical trial leaders at major cancer centers, IMPACT will help patients access clinical trials in their communities and educate local physicians about advances in genomics and precision medicine. The goal of each IMPACT grant is to increase clinical trial participation among blood cancer patients served by community cancer centers by at least 20 percent over a five-year period.

Pioneering New Models

LLS funds research from bench to bedside through collaborations, venture philanthropy and grants. This year, we invested $32 million of our research budget to support clinical trials, along with an additional $10.5 million to operate our Beat AML Master Clinical Trial, for a total investment of $42.5 million. Complementing our research agenda are policy and advocacy efforts that push for affordable clinical trial access and hold the FDA accountable for implementing clinical trial reforms enacted in the 21st Century Cures Act, including new rules on master trials.

LLS champions these pioneering models. Our Beat AML Master Clinical Trial demonstrates that personalized treatment using genomics can be assigned to patients based on their specific subtype in less than seven days. With its flexible, collaborative structure, the trial is testing several novel therapies in multiple study arms simultaneously. This patient-first trial design—developed with guidance from the FDA—has the potential to stand as a model for future cancer clinical trials. Now, LLS will bring our leadership in patient-centric clinical trials to pediatric acute leukemia and other blood cancers. We will also continue to ensure that patients’ needs and preferences are at the forefront of drug development to pave the way for better care and cures in the future.

LLS-funded researcher Selina Chen-Kiang, PhD, Weill Cornell Medicine, and her world-class team
I was armed with so much information. When you have information, you feel empowered. Every day, we learned more and that helped Meaghan take ownership of her health. I’d encourage anyone going through a blood cancer diagnosis to reach out to LLS. There is such an incredible network of support, and it’s so much better when you have someone in your corner.

— Maura Kilner, a caregiver for her daughter Meaghan, who was diagnosed with Hodgkin lymphoma in 2017

As a 2019 Honored Hero for Students of the Year, Meaghan inspired and motivated high school students in her community to raise funds for our mission.
Helping Patients Throughout Their Cancer Experience

Approximately every three minutes, someone in the U.S. is diagnosed with a blood cancer. When someone experiences the fear and uncertainty of a cancer diagnosis, we provide hope, guidance, education and support. LLS is dedicated to helping patients navigate their cancer treatments and access quality care.

Supporting Patients, Caregivers and Families

We are committed to patients, caregivers and families throughout their entire cancer experience. Here at LLS, we believe one-on-one support makes all the difference, so we offer a wide array of free resources to help patients find the support they need.

For more than two decades, LLS Information Specialists have been on the front lines of an ever-changing healthcare landscape, guiding patients and caregivers to our robust education and support services. Information Specialists are master’s level oncology professionals who provide free, personalized assistance to patients, families and healthcare providers. They offer guidance through cancer treatment, assist with financial and social challenges, and give accurate, up-to-date disease, treatment and support information. Information Specialists also refer patients to LLS Clinical Trial Nurse Navigators as appropriate.

According to an independent evaluation that concluded in 2019, 86 percent of patients and caregivers said they felt more hopeful and 83 percent said they felt more comfortable managing their or their loved one’s diagnosis after their first contact with an Information Specialist. This is an extraordinary testament to the impact of LLS’s one-on-one support.

We offer a variety of ways for patients and caregivers to find connections and support. This year, LLS:

- Connected more than 1,500 volunteers with patients and caregivers diagnosed with the same disease through LLS’s Patti Robinson Kaufmann First Connection Program
- Reached nearly 12,000 patients and caregivers registered on our online social network, LLS Patient Community
- Provided nearly 900 patients and caregivers with free, personalized nutrition consultations from our registered dietitian
- Distributed a new, comprehensive caregiver workbook in English and Spanish to 930 caregivers

Contact an Information Specialist for one-on-one support at 1.800.955.4572, and by live chat or email via www.LLS.org.
Volunteering with Myeloma Link gave me a way to heal from my cancer experience, while helping someone else in the process. A diagnosis is a stumbling block, but there is light at the end of the tunnel. For me, the support and education I received from LLS has been that light.

— Kelvin Yates, diagnosed with myeloma in 2014

In addition to providing direct support to patients, Kelvin participates in Light The Night.
Helping Patients Throughout Their Cancer Experience (cont.)

Educating Patients, Caregivers and Healthcare Professionals

LLS is here to help patients, caregivers and healthcare professionals stay informed and current on the latest disease, treatment and survivorship information. This year, LLS:

- Distributed more than 855,000 educational booklets and fact sheets about blood cancers and survivorship topics
- Educated more than 132,400 patients, caregivers, healthcare professionals and others through live web-based and local in-person programs
- Reached nearly 12,000 listeners through LLS podcasts, including The Bloodline with LLS for patients and caregivers, and Treating Blood Cancers, a new podcast for healthcare professionals

Investing in Health Services Research

LLS plans to boost our investment in health services research to understand and address concerns about quality of life and access to care during treatment and beyond. LLS is pursuing research into:

- The financial burden of treatment
- The services survivors or caregivers might need
- The preferences patients have when weighing treatment options
- The late effects survivors might be experiencing

This year, LLS received a three-year grant to fund a new intervention study by Carma Bylund, PhD, University of Florida, and her research team that aims to improve family and healthcare communication among adults who care for a parent with blood cancer. This work builds upon in-depth qualitative research completed by Dr. Bylund and LLS in 2018, which identified unique communication issues faced by these caregivers, including conflicts with siblings in negotiating caregiving responsibilities and navigating role reversals. As part of the intervention study, new online resources will launch on www.LLS.org in the next year to help caregivers of parents practice open, healthy communication with their families, find reliable cancer information online and communicate effectively with healthcare teams. Both research studies were funded by the Carolan Research Institute.

SPOTLIGHT ON MYELOMA LINK

African Americans have twice the incidence of myeloma as white Americans. Recent studies show that African Americans are significantly less likely to receive the latest treatments, and are more likely to experience treatment delays. LLS is dedicated to connecting African American communities to free myeloma information and support and enhancing access to care and the latest treatments through our Myeloma Link program. In 2019, the program expanded from two to eight cities, reaching more than 10,000 patients, caregivers and healthcare providers through over 100 awareness and education programs. Myeloma Link is just one part of our efforts to address the needs of underserved communities. LLS has committed $35.4 million in multi-year grants to accelerate impactful myeloma research to find cures.
LLS invests in research critical to achieving cancer treatment breakthroughs, which often requires decades of effort and financial support. While LLS is advancing efficient clinical trial designs and cost effective ways to produce groundbreaking treatments, we need to take action now to ensure that cancer patients can access lifesaving treatments.

Taking Bold Action for Patients

With the cost of cancer care skyrocketing, a growing portion of these costs is being shifted to patients. As a result, some patients are delaying or even forgoing treatment. Through our nationwide grassroots network of more than 50,000 active online volunteers, LLS works to break down barriers standing between patients and the care they need.

In 2017, LLS launched our Cost of Cancer Care Initiative with aggressive, yet feasible cost-cutting ideas that would save money without sacrificing quality care. We shared our ideas with stakeholders across the healthcare ecosystem because we believe all players need to do their part to put patients first.

Since then, our Office of Public Policy has made significant progress on many fronts, including:

- Bi-partisan support for proposals to lower out-of-pocket costs, especially for those enrolled in Medicare Part D
- Measures under consideration to promote value-based payments, so that the cost of service reflects its value
- Measures adopted to increase marketplace competition, such as allowing generic drugmakers to introduce less expensive versions of costly drugs sooner

LLS also advocates for meaningful health insurance coverage, so that patients can afford the treatments they need. We advance solutions that uphold our core principles for meaningful coverage: guarantee access, promote affordability, ensure quality and encourage stability.

In particular, LLS calls upon lawmakers to limit the spread of short-term, limited duration health insurance plans, which pose risks to patients and consumers by requiring them to pay exorbitant costs. We pushed back against these plans through multifaceted efforts, urging members of Congress, governors, state legislators and insurance commissioners to take action to protect patients.

Breaking Down Barriers to Care

Six months later, we saw progress on 75 percent of these recommendations, including:

- Bi-partisan support for proposals to lower out-of-pocket costs, especially for those enrolled in Medicare Part D
- Measures under consideration to promote value-based payments, so that the cost of service reflects its value
- Measures adopted to increase marketplace competition, such as allowing generic drugmakers to introduce less expensive versions of costly drugs sooner

PROTECTING MEANINGFUL HEALTH INSURANCE

While legislators debated proposals that would roll back access to meaningful health insurance coverage, LLS took action.

MORE THAN 16,700 LETTERS SENT BY LLS ADVOCATES

MORE THAN 725 COMPLETED CALLS MADE BY LLS ADVOCATES

HUNDREDS OF IN-PERSON MEETINGS CONDUCTED
“Policy change is needed to ensure that the patients I work with can access the care they need to live long and healthy lives. I’m proud to raise my voice with LLS and speak out on behalf of patients and their families.”

— Myra Davis-Alston, a passionate LLS volunteer advocate who brings her unique perspective as an oncology nurse to our policy and advocacy endeavors
Making a Difference

Through our financial assistance programs, we help patients and families navigate difficulties with insurance and co-pay burdens and cope with the often daunting financial challenges of cancer treatment. This year, LLS expanded the financial support we provide through two new programs to help blood cancer patients and their families when they need it most.

- The **LLS Urgent Need Program**, established in partnership with “Moppie’s Love,” is available to help pediatric and young adult blood cancer patients, or adult blood cancer patients enrolled in clinical trials, who are in acute financial need. The program provides a $500 grant to assist with non-medical expenses, including utilities, rent, mortgage, food, lodging, dental care, child care, elder care and other essential needs.

- The **LLS Patient Aid Program** provides financial assistance to blood cancer patients, regardless of their financial circumstances. Eligible patients receive a $100 stipend.

What patients and families are saying:

* "Without your financial and moral support, I wouldn’t be alive today. You help put food on my table and hope in my heart."*

* "LLS has been a wonderful help when a tough financial spot arose from our daughter’s long in-patient stay. The $500 [from the LLS Urgent Need Program] helped with our rent."*

* "Your program has been a saving grace for my parents. They planned for retirement and would have had everything wiped out had it not been for your service."*
Uncovering New Insights

Here at LLS, we believe no one should have to choose between seeking care and affording groceries or a mortgage. The cost of cancer care is becoming unsustainable for both cancer patients and the overall healthcare system. LLS is investing in more research to understand the financial burdens associated with the cost of blood cancer treatment and its long-term effects, as well as disparities in patients’ access to the latest treatments. Leading edge LLS-funded research projects include:

- **Rena Conti, PhD, Associate Research Director of Biopharma & Public Policy at the Boston University Institute for Health System Innovation & Policy**, is leading a study to understand better the range of financial difficulties experienced by patients with multiple myeloma or chronic lymphocytic leukemia who are undergoing or have forgone treatment at National Cancer Institute Community Oncology Research Program (NCORP) Minority/Underserved Community Sites across the country. Dr. Conti is also a Dean’s Research Scholar and Associate Professor of Markets, Public Policy and Law at the Boston University Questrom School of Business.

- **Stacie Dusetzina, PhD, Associate Professor of Health Policy and Ingram Associate Professor of Cancer Research at Vanderbilt**, is leading a two-year study jointly funded by LLS and The Commonwealth Fund on the impact of healthcare costs on the behavior of senior patients enrolled in Medicare. Her research is examining the association between delaying or never filling specialty drug prescriptions and health outcomes related to the disease being treated.

In addition, we commissioned two studies by the actuarial firm, Milliman, examining the factors that are driving blood cancer costs within the healthcare system as well as the out-of-pocket cost burden that patients experience. The findings showed, for example, that treatment of acute leukemia among commercially insured patients cost the healthcare system more than $800,000 on average in the first three years following a patient’s diagnosis. For patients with Medicare coverage, those being treated for lymphoma spent as much as $19,000 out-of-pocket on medical costs in the first year following their diagnosis, while those with myeloma spent $24,000 on average in the first two years following diagnosis.

These extraordinary costs underscore the simple fact that meaningful insurance coverage is a necessity for virtually anyone in need of blood cancer treatment. The high cost of care is also a reminder that as we make advancements in the treatment of blood cancer, we must pursue policies that ensure those treatments are accessible to the patients who need them. To learn more about our Cost of Cancer Care Initiative, please visit www.LLS.org/cancercost.

▼ LLS-funded researcher Dr. Rena Conti
For generations of families and children, our signature fundraising campaigns have helped LLS find cures and ensure access to treatments for blood cancer patients nationwide. We are inspiring people across the country to run, hike, walk, sail, build teams and gain lifelong learning skills while raising funds to drive forward our mission. This year, LLS is featured once again in *The Chronicle of Philanthropy*'s “America’s Favorite Charities,” and jumped from number 61 last year to number 39 in 2019, showcasing one of the highest growth rates in charitable contributions (34 percent). Among charities with a health focus, LLS is ranked sixth on the list.

For more than 30 years, LLS has been a pioneer in creating unique and innovative peer-to-peer fundraising campaigns.

**The Leukemia Cup Regatta**, a thrilling series of events that combines the joy of on-water sports with the important task of raising money to cure cancer, commenced in 1988. Skippers and their crews participate in more than 45 regattas nationwide.

LLS’s flagship campaign **Team In Training®** was formed in 1988. From there, Team In Training has gone on to set the standard for endurance sports fundraising programs worldwide. More than 650,000 teammates have run, walked, hiked, cycled, climbed and competed in triathlons.

**Man & Woman of the Year**, a philanthropic competition, launched in 1990. Now taking place in nearly 100 communities across the country, the campaign brings together a passionate group of individuals and their teams for an exciting 10-week philanthropic competition to win the title of “Man or Woman of the Year.”

DRIVING SUPPORT ACROSS THE COUNTRY
Since 1993, children have experienced the satisfaction that comes from helping others by fundraising in honor of local, school-aged patients battling blood cancers. More than 14.5 million students, families and educators in 27,000 schools across the U.S. participate annually in programs, such as Pennies for Patients.

Light The Night® kicked off nationwide in 1999 and is now the fifth largest peer-to-peer fundraising program in the U.S. One million friends, families and co-workers gather together and bring light to the darkness of cancer, carrying illuminated lanterns in 140 inspirational evening walks to celebrate, honor or remember those touched by cancer.

New innovative fundraising campaign Students of the Year launched nationally in 2017 and is helping to foster committed young philanthropists and redefine what giving looks like in today’s charity and community service environment.

LLS Lifestyle, initiated in 2017, is a new peer-to-peer fundraising platform that enables LLS supporters to get creative and start their own movement. In its inaugural year, participants turned their creative ideas into impactful fundraising activities in support of LLS.
We are grateful to our partners and sponsors, who harness the power of their consumers, communities and employees to help fight blood cancers. Some of our top partners include:

**Burlington Stores, Inc.**

For the past 17 years, LLS has partnered with Burlington to host an in-store point-of-sale campaign that raises funds to further the LLS mission. Through this campaign, Burlington associates ask customers to donate $1 or more at checkout to raise critical funds for research and patient support that help to save lives and bring smiles to the faces of children and families impacted by blood cancer. Burlington is our number one National Corporate Partner and Honored Friend, having raised more than $37 million since 2002.

**United Food and Commercial Workers Union (UFCW)**

UFCW takes great pride in the longstanding partnership with LLS—37 years and more than $90 million raised. The Labor Against Cancer initiative, launched in 2017, features a fundraising drive among members, retail campaigns and walking to end cancer with LLS’s Light The Night, and represents an unprecedented effort to mobilize more than one million members and their families to build awareness and help raise funds.

**Walgreens**

Walgreens has been collaborating with and supporting LLS since 2016, providing education and resources for patients and their families who are living with blood cancer; this includes training and certification for specialty pharmacists and sponsoring our Blood Cancer Conferences. Walgreens’ commitment extends far beyond patient and professional education. Last year, more than 6,500 Walgreens stores participated in fundraisers that raised $2.6 million for LLS. Nearly 250 Walgreens teams around the country also participated in Light The Night.
Subaru

Together, Subaru retailers and local LLS staff deliver co-branded blankets and arts and crafts kits to adults and children fighting cancer along with “message of hope” cards signed by visitors to the retailers, offering words of encouragement and hope. Since 2016, LLS and Subaru have donated more than 148,000 blankets and 21,500 arts and crafts kits and reached nearly 150,000 patients in more than 780 hospitals, with the help of more than 540 Subaru retailers nationwide.

WAWA

Wawa and The Wawa Foundation are proud partners of LLS, holding in-store customer engagement fundraising each year to benefit Light The Night. In 2018, The Wawa Foundation committed to presenting-level sponsorship support in both Philadelphia and Washington, D.C. Additionally, the Foundation recently announced a $1 million grant to The LLS Children’s Initiative to accelerate new and better treatments for pediatric blood cancers.
Celebrating a Beat AML Victory

This year, LLS achieved a historic milestone: we met our ambitious fundraising goal of $125 million for Beat AML. Donors, volunteers, supporters, Beat AML project leads, and LLS staff and leadership gathered to celebrate at two festive events: one in New York City and the other in San Francisco.

Hosting the events, Dr. Louis DeGennaro declared: “I call it a victory, because that is exactly what this is. We took on the challenge of leading a global initiative to find new treatments for a cancer that had not seen real progress in four decades. And because of all of you, we are victorious and will continue to fight this battle.”

The evenings highlighted how this, the first-ever capital campaign held by LLS, is a real game-changer—and not just for LLS but for the entire medical field. With our donors and partners, Beat AML advanced novel science and validated a revolutionary master clinical trial model that puts patients at the center of the research paradigm.

And, it opened the door for further advances in acute myeloid leukemia through continued Beat AML efforts, as well as the launch of The LLS Children’s Initiative.

Beat AML demonstrates the power of philanthropy at LLS.

Honoring the life and contribution of campaign vice-chair, John Kellenyi, Michael Copley, national chair, spoke of John’s impact. “The campaign would not have been the same without John,” said Michael. “He was the most amazing fundraiser, friend and human being. John took tremendous pride in knowing what he did furthered the LLS mission by improving and saving the lives of patients.”

From left: Cristina Kellenyi, Dr. Louis DeGennaro, Teresita Kellenyi, Michael Copley

“Our son Michael passed away in 2008 from AML and our goal is to support better treatments and results through the work of LLS and the Beat AML initiative. We want people who are diagnosed with AML to know that there is hope!”

— Kelly Treinen, The Michael Treinen Foundation, Noblesville, Indiana

“After losing our beloved son and brother Robert Lyon to AML in 2007, we dedicated our family foundation to supporting AML research to ensure that those facing
the same diagnosis have far better odds at beating the disease. With the Beat AML initiative in full swing, the Lyon Family Foundation is even more focused on disrupting the current trajectory for these patients and seeing treatment change at a really rapid rate!"
— Lyon Family, Chicago, Illinois

“Women are changing the world through our growing leadership and strategic philanthropy. Collectively we’re going to have a greater impact than alone. That is why we have launched Women Curing Cancer, a community of women seeking to accelerate cancer cures, especially for children. We believe the way to cure cancer is to identify the best and brightest researchers and support the most innovative and promising projects. Together, we can drive incredible progress in science and medicine.”
— Lynne O’Brien and Evelyn Bata, PhD, Co-founders, Women Curing Cancer

Women Curing Cancer is a group of women leaders who are partnering with LLS to accelerate cancer cures.

“My journey with LLS began in 2008 right after going through the frightening diagnosis of non-Hodgkin lymphoma. I heard about LLS’s Team in Training and I felt I could use my personal experience to raise money for a more than worthy cause. I later served on the Long Island Chapter’s Board of Trustees and learned about the funding needed for research, which is the only way to find a cure for all blood cancers. I decided to make a personal gift directly to research while also continuing my fundraising crusade for Team In Training. LLS has changed my life and will always be a part of my life as well as my family’s.”
— Gary Trovato, Long Island
Our lifesaving work would not be possible without volunteers. Each day, volunteers across the country give their time and talent to activities that support our mission. Their efforts are game changing: they provide the leadership, big ideas and dedication we need to beat cancer.

LLS volunteers are part of a diverse and vibrant community of supporters who represent all walks of life and bring different experiences and passions to drive forward our mission. With countless ways to engage, from raising critical funds, to advocating for lifesaving policies, to providing support to those impacted by cancer, our volunteers are truly making a difference.

Since we started in 1949, the partnerships between volunteers and staff have been at the heart of our quest to find cancer cures. That’s why LLS is committed to recognizing and engaging volunteers who support every facet of our organization.

This year, LLS launched Volunteers in Action (VIA), a new online and mobile platform that will help us do exactly that. VIA empowers volunteers throughout their journey with LLS, connecting them to the tools, resources and people they need to create impact. With VIA, volunteers can see the impact of their time, sign up for the latest opportunities and interact with staff and other volunteers who share their interests.

If you volunteer with LLS or have in the past, thank you for your incredible partnership. You inspire us to work tirelessly toward our mission every single day.

If beating cancer is in your blood, we have a rewarding volunteer opportunity for you – whatever your interests, skills or time commitments.

Learn more at www.volunteerLLS.org.
We’ve met amazing people through LLS and built so many relationships, especially with Man & Woman of the Year candidates—some of whom are survivors themselves. And we’ve met others who don’t have a connection, but just want to help. Becoming part of the LLS community has been such an amazing experience for our family."

— Rachel Dacanay-Smith, mother of Lucia, who was diagnosed with acute promyelocytic leukemia in 2018

After enduring an intense, nine-month treatment regimen, Lucia’s cancer went into complete remission. As the 2019 Girl of the Year for LLS’s National Capital Area Chapter, Lucia inspired Man & Woman of the Year candidates to raise significant funds and awareness.
Independent Auditors’ Report

The Board of Directors
The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated financial statements of The Leukemia & Lymphoma Society, Inc. (LLS), which comprise the consolidated balance sheet as of June 30, 2019, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Consolidated Financial Statements
Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility
Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2019, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

Emphasis of Matter
As discussed in note 1(t) to the consolidated financial statements, in 2019 The Leukemia & Lymphoma Society, Inc. adopted new accounting guidance, Accounting Standards Update 2016-14, Presentation of Financial Statements of Not-for-Profit Entities. Our opinion is not modified with respect to this matter.

Report on Summarized Comparative Information
We have previously audited the The Leukemia & Lymphoma Society, Inc. 2018 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated November 7, 2018. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2018 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived before the adjustments to adopt Accounting Standards Update 2016-14, Presentation of Financial Statements of Not-for-Profit Entities. As part of our audit of the 2019 consolidated financial statements, we also audited the adjustments described in note 1(t) that were applied to adopt Accounting Standards Update 2016-14, Presentation of Financial Statements of Not-for-Profit Entities retrospectively in the 2018 consolidated financial statements. In our opinion, such adjustments are appropriate and have been properly applied.

November 5, 2019
## Consolidated Balance Sheet

The Leukemia & Lymphoma Society, Inc. / June 30, 2019 (with comparative amounts at June 30, 2018) (In thousands)

### Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$24,735</td>
<td>$27,628</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>$4,653</td>
<td>$2,767</td>
</tr>
<tr>
<td>Contribution and other receivables, net (note 7)</td>
<td>$15,489</td>
<td>$32,255</td>
</tr>
<tr>
<td>Investments (note 4)</td>
<td>$407,903</td>
<td>$319,662</td>
</tr>
<tr>
<td>Fixed assets, net (note 10)</td>
<td>$9,161</td>
<td>$8,614</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$461,941</strong></td>
<td><strong>390,926</strong></td>
</tr>
</tbody>
</table>

### Liabilities and Net Assets

**Liabilities:**

<table>
<thead>
<tr>
<th>Description</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$23,487</td>
<td>$21,907</td>
</tr>
<tr>
<td>Deferred revenue (note 8)</td>
<td>$13,739</td>
<td>$16,243</td>
</tr>
<tr>
<td>Awards and grants payable (note 2)</td>
<td>$50,974</td>
<td>$51,673</td>
</tr>
<tr>
<td>Co-Pay assistance payable (note 3)</td>
<td>$94,957</td>
<td>$54,696</td>
</tr>
<tr>
<td>Other long-term liabilities (note 11)</td>
<td>$4,715</td>
<td>$3,835</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>$187,872</strong></td>
<td><strong>$148,354</strong></td>
</tr>
</tbody>
</table>

**Commitments and contingencies (notes 2, 3, 12 and 14)**

**Net assets:**

<table>
<thead>
<tr>
<th>Description</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Without donor restrictions</td>
<td>$178,099</td>
<td>$149,199</td>
</tr>
<tr>
<td>With donor restrictions (notes 3 and 6)</td>
<td>$95,970</td>
<td>$93,373</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>$274,069</strong></td>
<td><strong>$242,572</strong></td>
</tr>
</tbody>
</table>

**Total liabilities and net assets**

<table>
<thead>
<tr>
<th>Description</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td><strong>$461,941</strong></td>
<td><strong>390,926</strong></td>
</tr>
</tbody>
</table>

*See accompanying notes to consolidated financial statements.*
## Consolidated Statement of Activities

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2019  
(with summarized totals for the year ended June 30, 2018) (In thousands)

### Operating revenue:

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total 2019</th>
<th>Total 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$ 273,691</td>
<td>20,832</td>
<td>294,523</td>
<td>282,108</td>
</tr>
<tr>
<td>Less direct donor benefit costs</td>
<td>(29,624)</td>
<td></td>
<td>(29,624)</td>
<td>(29,198)</td>
</tr>
<tr>
<td>Net campaign contributions</td>
<td>244,067</td>
<td>20,832</td>
<td>264,899</td>
<td>252,910</td>
</tr>
<tr>
<td>Co-Pay contributions (note 3)</td>
<td></td>
<td>90,930</td>
<td>90,930</td>
<td>159,851</td>
</tr>
<tr>
<td>Therapy Acceleration Program contractual return</td>
<td>4,495</td>
<td></td>
<td>4,495</td>
<td>3,855</td>
</tr>
<tr>
<td>Service revenue</td>
<td>14,936</td>
<td></td>
<td>14,936</td>
<td>9,230</td>
</tr>
<tr>
<td>Donated services, goods and media (note 9)</td>
<td>11,987</td>
<td></td>
<td>11,987</td>
<td>7,715</td>
</tr>
<tr>
<td>Legacies and other revenue</td>
<td>6,721</td>
<td>13,187</td>
<td>19,908</td>
<td>11,018</td>
</tr>
<tr>
<td>Net interest and dividend income</td>
<td>5,265</td>
<td>1,921</td>
<td>7,186</td>
<td>4,316</td>
</tr>
<tr>
<td>Net assets released from restrictions:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Pay assistance (note 3)</td>
<td>102,057</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Satisfaction of other donor restrictions</td>
<td>22,456</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total operating revenue</td>
<td>411,984</td>
<td>2,357</td>
<td>414,341</td>
<td>448,895</td>
</tr>
</tbody>
</table>

### Operating expenses:

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total 2019</th>
<th>Total 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program services:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research</td>
<td>71,119</td>
<td></td>
<td>71,119</td>
<td>66,865</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>153,138</td>
<td></td>
<td>153,138</td>
<td>162,707</td>
</tr>
<tr>
<td>Public health education</td>
<td>45,130</td>
<td></td>
<td>45,130</td>
<td>39,557</td>
</tr>
<tr>
<td>Professional education</td>
<td>14,500</td>
<td></td>
<td>14,500</td>
<td>16,425</td>
</tr>
<tr>
<td>Total program services</td>
<td>283,887</td>
<td></td>
<td>283,887</td>
<td>285,554</td>
</tr>
<tr>
<td>Supporting services:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management and general</td>
<td>54,258</td>
<td></td>
<td>54,258</td>
<td>44,698</td>
</tr>
<tr>
<td>Fund raising</td>
<td>49,101</td>
<td></td>
<td>49,101</td>
<td>42,342</td>
</tr>
<tr>
<td>Total supporting services</td>
<td>103,359</td>
<td></td>
<td>103,359</td>
<td>87,040</td>
</tr>
<tr>
<td>Total operating expenses</td>
<td>387,246</td>
<td></td>
<td>387,246</td>
<td>372,594</td>
</tr>
<tr>
<td>Change in net assets from operating activities</td>
<td>24,738</td>
<td>2,357</td>
<td>27,095</td>
<td>76,301</td>
</tr>
<tr>
<td>Foreign currency translation adjustment and other</td>
<td>(38)</td>
<td>1</td>
<td>(37)</td>
<td>(99)</td>
</tr>
<tr>
<td>Net increase in fair value of investments</td>
<td>4,200</td>
<td>239</td>
<td>4,439</td>
<td>7,060</td>
</tr>
<tr>
<td>Change in net assets</td>
<td>28,900</td>
<td>2,597</td>
<td>31,497</td>
<td>83,262</td>
</tr>
</tbody>
</table>

### Net Assets:

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total 2019</th>
<th>Total 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning of period</td>
<td>149,199</td>
<td>93,373</td>
<td>242,572</td>
<td>159,310</td>
</tr>
<tr>
<td>End of period</td>
<td>$ 178,099</td>
<td>95,970</td>
<td>274,069</td>
<td>242,572</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
# Consolidated Statement of Functional Expenses

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2019 (with comparative totals for the year ended June 30, 2018) (In thousands)

## Program Services

<table>
<thead>
<tr>
<th>Research</th>
<th>Patient and community service</th>
<th>Public health education</th>
<th>Professional education</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awards and grants</td>
<td>$45,687</td>
<td>—</td>
<td>—</td>
<td>45,687</td>
</tr>
<tr>
<td>Therapy acceleration program</td>
<td>2,433</td>
<td>—</td>
<td>—</td>
<td>2,433</td>
</tr>
<tr>
<td>Clinical trial</td>
<td>10,468</td>
<td>—</td>
<td>—</td>
<td>10,468</td>
</tr>
<tr>
<td>Financial aid to patients</td>
<td>—</td>
<td>4,228</td>
<td>—</td>
<td>4,228</td>
</tr>
<tr>
<td>Co-Pay assistance</td>
<td>—</td>
<td>97,151</td>
<td>—</td>
<td>97,151</td>
</tr>
<tr>
<td>Co-Pay processing fees</td>
<td>—</td>
<td>4,088</td>
<td>—</td>
<td>4,088</td>
</tr>
<tr>
<td>Donated services, goods and media</td>
<td>628</td>
<td>2,572</td>
<td>3,786</td>
<td>222</td>
</tr>
<tr>
<td>Salaries and employee benefits and taxes</td>
<td>4,969</td>
<td>27,744</td>
<td>22,993</td>
<td>8,505</td>
</tr>
<tr>
<td>Professional fees</td>
<td>4,755</td>
<td>4,803</td>
<td>4,606</td>
<td>2,042</td>
</tr>
<tr>
<td>Printing, advertising, and supplies</td>
<td>133</td>
<td>3,611</td>
<td>5,809</td>
<td>1,046</td>
</tr>
<tr>
<td>Occupancy, telephone and insurance</td>
<td>222</td>
<td>3,147</td>
<td>2,775</td>
<td>908</td>
</tr>
<tr>
<td>Travel and meetings</td>
<td>614</td>
<td>2,221</td>
<td>2,056</td>
<td>1,005</td>
</tr>
<tr>
<td>Equipment rentals and maintenance</td>
<td>1,005</td>
<td>739</td>
<td>336</td>
<td>136</td>
</tr>
<tr>
<td>Postage and shipping</td>
<td>23</td>
<td>1,408</td>
<td>1,693</td>
<td>229</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>174</td>
<td>1,285</td>
<td>949</td>
<td>368</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>8</td>
<td>141</td>
<td>127</td>
<td>39</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>$71,119</strong></td>
<td><strong>153,138</strong></td>
<td><strong>45,130</strong></td>
<td><strong>14,500</strong></td>
</tr>
</tbody>
</table>

## Supporting Services

<table>
<thead>
<tr>
<th>Management and general</th>
<th>Fund raising</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awards and grants</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Therapy acceleration program</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Clinical trial</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Financial aid to patients</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Co-Pay assistance</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Co-Pay processing fees</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Donated services, goods and media</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Salaries and employee benefits and taxes</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Professional fees</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Printing, advertising, and supplies</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Occupancy, telephone and insurance</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Travel and meetings</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Equipment rentals and maintenance</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Postage and shipping</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>$54,258</strong></td>
<td><strong>49,101</strong></td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
## Consolidated Statement of Cash Flows

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2019  
(with comparative amounts for the year ended June 30, 2018)  
(In thousands)

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$31,497</td>
<td>83,262</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash provided by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net increase in fair value of investments</td>
<td>(3,497)</td>
<td>(7,341)</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>4,364</td>
<td>5,499</td>
</tr>
<tr>
<td>Provision for uncollectible accounts</td>
<td>396</td>
<td>(630)</td>
</tr>
<tr>
<td>Changes in operating assets and liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>(1,886)</td>
<td>846</td>
</tr>
<tr>
<td>Contributions and other receivables, net</td>
<td>16,370</td>
<td>(13,840)</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>1,580</td>
<td>196</td>
</tr>
<tr>
<td>Other long-term liabilities</td>
<td>880</td>
<td>668</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>(2,504)</td>
<td>2,215</td>
</tr>
<tr>
<td>Awards and grants payable</td>
<td>(699)</td>
<td>(12,379)</td>
</tr>
<tr>
<td>Co-Pay assistance payable</td>
<td>40,261</td>
<td>34,625</td>
</tr>
<tr>
<td>Net cash provided by operating activities</td>
<td>86,762</td>
<td>93,121</td>
</tr>
</tbody>
</table>

| **Cash flows from investing activities:** |           |           |
| Purchases of fixed assets        | (4,911)   | (3,994)   |
| Purchases of long-term investments | (92,600)  | (150,533) |
| Sales of investments             | 7,856     | 47,633    |
| Net cash used in investing activities | (89,655) | (106,894) |
| Net decrease in cash and cash equivalents | (2,893)   | (13,773)  |
| Cash and cash equivalents at beginning of period | 27,628    | 41,401    |
| Cash and cash equivalents at end of period | $24,735   | 27,628    |

See accompanying notes to consolidated financial statements.
1) Organization and Summary of Significant Accounting Policies

(a) Organization
The Leukemia & Lymphoma Society, Inc. (LLS) is the world’s largest voluntary health agency dedicated to finding cures for blood cancers and providing services to blood cancer patients, their families, and caregivers. LLS’s mission is to cure leukemia, lymphoma, Hodgkin’s disease, and myeloma and improve the quality of life of patients and their families. LLS research grants have funded many of today’s most promising advances for the treatment of blood cancer patients, including targeted therapies and immunotherapies. LLS is a leading source of publicly available information regarding blood cancer and education and support programs. LLS influences public policies that accelerate the development and approval of new blood cancer therapies and advocates for all blood cancer patients and their families, helping patients navigate their cancer treatments and access to quality, affordable and coordinated care. LLS is dedicated to removing barriers to care by representing the healthcare and medical research interests of patients and families to policy makers at all levels of government.

(b) Principles of Consolidation
The accompanying consolidated financial statements include the accounts of LLS that encompass the National Office of LLS and its fifty six chapters in the United States, and LLS’s not for profit affiliates, including The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) and its five chapters in Canada, The Leukemia & Lymphoma Society Research Programs, Inc. (LLSRP), The Leukemia & Lymphoma Society Research Foundation (LLSRF), and PearlPoint Cancer Support, Inc. (PPCS). Effective March 28, 2016, LLS became the sole member of PPCS. Effective February 8, 2018, PPCS was dissolved. All significant intercompany and intra LLS accounts and transactions have been eliminated in consolidation.

(c) Tax-Exempt Status
LLS, LLSRP and LLSRF qualify as charitable organizations as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, are exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since these organizations are publicly supported, contributions qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

LLSC is registered as a charitable organization under the Income Tax Act (Canada) and is, therefore, not subject to income taxes if certain disbursement requirements are met.

LLS and its related entities recognize the effect of income tax positions only if those tax positions are more likely than not to be sustained. Income generated from activities unrelated to exempt purposes are subject to tax under Internal Revenue Code Section 511. There were no entities that recognized any unrelated business income tax liability for the years ended June 30, 2019 and 2018.

(d) Estimates
The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires LLS’s management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The significant estimates made in the preparation of these consolidated financial statements include allocation of expenses, and valuation of donated goods, services and media. Actual results could differ from those estimates.
(e) Risks and Uncertainties

LLS invests in various investment securities. Investment securities are exposed to various risks such as interest rate risks, fluctuations in market values, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the consolidated balance sheet.

LLS’s principal source of revenue is contributions by the general public. Accordingly, LLS’s operations are dependent upon individual contributions, that are affected by general economic conditions, employment levels, and other factors over which LLS has little or no control. By contrast to the granularity of the general public donations, the Co Pay program in 2019 and 2018 was funded by six donors, respectively. In addition, the Beat AML Master Trial was primarily funded by seven donors in 2019 and 2018, respectively.

(f) Summarized Financial Information

The consolidated financial statements are presented with 2018 summarized information. With respect to the consolidated statement of activities, such prior year information is not presented by net asset class and, in the consolidated statement of functional expenses, 2018 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with LLS’s 2018 consolidated financial statements from which the summarized information was derived.

(g) Subsequent Events

LLS evaluated subsequent events after the balance sheet date of June 30, 2019 through November 5, 2019, which was the date the consolidated financial statements were issued, and concluded that no additional disclosures are required.

(h) Net Asset Classifications

To ensure observance of limitations and restrictions placed on the use of resources available to LLS, funds that have similar characteristics have been classified into two net asset categories as follows:

Net assets without donor restrictions: Consist of funds that are fully available, at the discretion of LLS’s Board of Directors, for LLS to utilize in any of its programs or supporting services.

Net assets with donor restrictions: Consist of funds that are restricted by donors for a specific time period and/or purpose. Also included in this category are net assets subject to donor imposed restrictions, which stipulate that the principal be maintained by LLS, but permits LLS to expend part or all of the income and gains derived there from. Expirations of restrictions are reported as net assets released from restrictions when the donor stipulated purpose has been fulfilled and/or the amount has been appropriated in compliance with the Board approved spending policy (note 6).

Revenue and gains and losses on investments and other assets and liabilities are reported as changes in net assets without restrictions unless limited by explicit donor imposed restrictions or by law. Expenses are reported as decreases in net assets without donor restrictions.

LLS delineates changes in net assets without donor restrictions as operating or non operating activities. Operating activities include all operating revenues and expenses that are an integral part of its programs and supporting activities and net assets released from donor restrictions to support operating expenditures. The measure of operations include support for operating activities from both with donor restrictions and without donor restrictions designated for long term investment according to LLS’s spending rate policy (note 6). Non operating activities include changes in fair value of investments and foreign currency translation adjustment and other nonrecurring items.

(i) Foreign Currency Translation

LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency translation of the financial statements of LLSC to U.S. dollars is included as a translation adjustment in the consolidated statement of activities.

(continues »)
(j) Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The three levels of the fair value hierarchy are as follows:

- **Level 1** inputs are quoted or published prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.
- **Level 2** inputs other than quoted or published prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- **Level 3** unobservable inputs for the asset or liability.

LLS follows the provisions of Accounting Standards Codification (ASC) 820, Fair Value Measurement, for its alternative investments that do not have readily determinable fair values, including hedge funds, limited partnerships, and other funds. This guidance allows, as a practical expedient, for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value, using net asset value (NAV) per share or its equivalent, as reported by the investment managers.

The classification of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment’s underlying assets and liabilities.

(k) Contributions, Grants and Deferred Revenue

Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as revenues with donor restrictions. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statement of activities as net assets released from restrictions.

Contributions expected to be received after one year are discounted at a risk adjusted rate of return. Amortization of the discount is recorded as additional contribution revenue in accordance with the donor imposed restrictions, if any, on the contributions.

Conditional contributions are recognized as revenue when the conditions have been substantially met. Certain grants are accounted for as exchange transactions whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

(l) Service Revenue

Service revenue is accounted for as an exchange transaction whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

(m) Donated Goods and Services

LLS has determined that certain of the donated goods and services it receives meet the criteria for recognition in the consolidated financial statements. The value of contributed goods was determined based on fair market value estimates. The value of contributed services was determined for volunteers that possess specialized skills, and would otherwise need to be purchased. These goods and services are recognized as revenue and expense (note 9).
(n) Donated Media
LLS has conducted national public service announcements (PSA) media campaigns and benefited from donated media time that was aired on television and radio. The value of contributed media, which is recognized in the consolidated financial statements, was estimated based on the placement, audience, and demographics of the PSA’s (note 9).

(o) Cash Equivalents
Cash equivalents consist of short term investments with an original maturity of three months or less from date of purchase, except for amounts held in investments.

(p) Investments
Investments are stated at fair value based upon quoted or published market prices, except for the fair values of alternative investments which are based on NAVs provided by the fund managers or general partners, based upon the underlying net assets of the funds consistent with the concepts of ASC 820. These values are reviewed and evaluated by management.

(q) Fixed Assets and Depreciation
Fixed assets, which consist principally of equipment, software, and leasehold improvements, are recorded at cost, and are depreciated or amortized using the straight line method over the estimated useful lives of the assets or the terms of the leases, if shorter, ranging 2 to 10 years (leasehold improvements 7 years; furniture, fixtures, and office equipment 7 to 10 years; and computer equipment and software 2 to 5 years).

(r) Other Long Term Liabilities
Other long term liabilities represent LLS’s liability for the Internal Revenue Code Section 457 deferred compensation plans recorded at fair market value (note 11), straight line rent of office leases (note 12), and capital leases.

(s) Professional Fees
Professional fees included in the consolidated financial statements principally include professional fund raising fees, contracted software development, and legal and auditing fees.

(t) Adopted Accounting Pronouncements
The FASB issued Accounting Standards Update (ASU) 2016 14, Presentation of Financial Statements of Not for Profit Entities, which among other things, changes how not for profit entities report net asset classes, expenses and liquidity in their financial statements. LLS adopted the main provisions of this guidance which include, the reduction of the number of net asset classes from three to two: with donor restrictions, previously reported as temporarily restricted net assets of $90,221 and permanently restrictions net assets of $3,152, in 2018, and without donor restrictions, previously reported as unrestricted net assets of $149,199, in 2018; the presentation of expenses by their function and their natural classification in one location; and quantitative and qualitative information about the management of liquid resources and availability of financial assets to meet cash needs within one year of the balance sheet date.

(continues »)
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

(u) Upcoming Accounting Standards

ASU No. 2014 09, Revenue from Contract with Customers (Topic 606) – This ASU, effective for LLS’s fiscal year ending June 30, 2020, will require LLS to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which LLS expects to be entitled in exchange for those goods or services. Management is evaluating the effect ASU 2014 09 will have on its consolidated financial statements.

ASU No. 2018 08, Not for Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contribution Received and Contributions Made – This ASU, effective for the LLS’s fiscal year ending June 30, 2020, is intended to clarify how entities determine whether to account for a transfer of assets (or a reduction, settlement, or cancellation of a liability) as an exchange transaction or a contribution based on whether commensurate value has been received or transferred. The new guidance also clarifies that a contribution is conditional if the agreement includes both a barrier that must be overcome for the recipient to be entitled to the assets transferred and a right of return for the transferred assets or a right of release of a promisor’s obligation to transfer assets. Management is evaluating the effect ASU 2018 08 will have on its consolidated financial statements.

ASU No. 2016 02, Leases (Topic 842) – This guidance, effective for LLS’s fiscal year ending June 30, 2022, requires a lessee to recognize a right of use asset and a lease liability, initially measured at the present value of the lease payments on the consolidated balance sheet and disclosing key information about leasing arrangements. Management is evaluating the effect ASU 2016 02 will have on its consolidated financial statements.

(v) Functional Allocation of Expense

The costs of providing the various programs and other activities have been summarized on a functional basis. Accordingly certain costs attributable to more than one program or supporting services function are allocated using cost allocation methods such as square footage and estimate of time and effort.

LLS allocates expenses relating to the operation and maintenance of plant and depreciation using building square footage based on functional use.

2) Research

LLS has various activities that are utilized to carry out its mission as presented below:

Research:

Awards and Grants: Awards and grants for research are approved by LLS’s Board of Directors and are recognized as expense when contractual conditions have been satisfied. The budgets for multi year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS’s Board of Directors. LLS has multi year grant commitments of $39,093 at June 30, 2019, which are conditioned upon future events and, accordingly, are not recorded. LLS has unconditional grants payable of $50,974 and $51,673 at June 30, 2019 and 2018, respectively, which are anticipated to be paid in the next year. Grant refunds of approximately $1,665 and $984 as of June 30, 2019 and 2018, respectively, have been netted against awards and grants expense.

Therapy Acceleration Program (TAP):

TAP is LLS’s strategic initiative to speed the development of blood cancer treatments and supportive diagnostics by creating business alliances with biotechnology and pharmaceutical companies. TAP provides funding for investigational new drug enabling studies and clinical stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multi year contracts, which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of LLS’s Board of Directors. LLS has contract commitments of $14,471 and $12,745 at June 30, 2019 and 2018, respectively, that are conditioned upon future events and, accordingly, are not recorded. Grant refunds of approximately $320 and $591 as of June 30, 2019 and June 30, 2018, respectively, have been netted against therapy acceleration program contractual return.

(continues »)
Commitments for the awards and grants and TAP programs are contingent upon the satisfactory completion of milestones and/or other conditions in the grant and contract agreements. If such conditions are satisfied, the amounts are estimated to be paid as follows:

<table>
<thead>
<tr>
<th>Year ending June 30</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>$30,206</td>
</tr>
<tr>
<td>2021</td>
<td>17,868</td>
</tr>
<tr>
<td>2022</td>
<td>5,323</td>
</tr>
<tr>
<td>2023 and thereafter</td>
<td>167</td>
</tr>
<tr>
<td>Total</td>
<td>$53,564</td>
</tr>
</tbody>
</table>

For the year ended June 30, 2019 and 2018, LLS received $4,495, and $3,855 of TAP contractual returns from various TAP contracts.

### 3) Co-Pay Assistance Program

Co-Pay Assistance Program: The Co-Pay Assistance program offers financial assistance to patients in meeting their insurance Co-Pay obligations for prescription medications or private/public health insurance premiums. Revenue is recognized when donations are received while expenses are recognized as patient applications are approved for participation according to program criteria and on availability of funding. The Co-Pay Assistance payable of $94,957 and $54,696 has been established based on approved patient applications received through June 30, 2019 and 2018, respectively. At June 30, 2019, net assets with donor restrictions include $43,279 received through June 30, 2019, which are available for expenditure and are intended to be awarded in future periods.

The following summarizes the activities of the Co-Pay Assistance program as of June 30, 2019.

<table>
<thead>
<tr>
<th></th>
<th>June 30, 2019</th>
<th>June 30, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning balance</td>
<td>$52,528</td>
<td>8,148</td>
</tr>
<tr>
<td>Contributions</td>
<td>90,930</td>
<td>159,851</td>
</tr>
<tr>
<td>Investment Gains</td>
<td>1,878</td>
<td>326</td>
</tr>
<tr>
<td>Total</td>
<td>145,334</td>
<td>222,221</td>
</tr>
<tr>
<td>Amount expended during the year:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct assistance to patients</td>
<td>$(97,151)</td>
<td>$(108,442)</td>
</tr>
<tr>
<td>Other expenses incurred and reimbursed under the contract</td>
<td>$(4,906)</td>
<td>$(7,355)</td>
</tr>
<tr>
<td>Amounts available for expenditures in subsequent periods</td>
<td>$43,279</td>
<td>$52,528</td>
</tr>
</tbody>
</table>

(continues »)
The following tables present LLS’s fair value hierarchy of investments measured at fair value on an annual basis as of June 30, 2019 and June 30, 2018:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money market funds and cash</td>
<td>$ 239,287</td>
<td>239,287</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Fixed income:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corporate bonds</td>
<td>63,201</td>
<td>63,201</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Equities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large cap equity</td>
<td>39,198</td>
<td>39,198</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>International equity</td>
<td>26,695</td>
<td>26,695</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Small/mid cap equity</td>
<td>26,273</td>
<td>26,273</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Commodities</td>
<td>4,935</td>
<td>4,935</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>399,589</td>
<td>399,589</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Investments reported at NAV:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multi strategy hedge funds</td>
<td>8,314</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$ 407,903</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money market funds and cash</td>
<td>$ 158,371</td>
<td>158,371</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Fixed income:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corporate bonds</td>
<td>56,758</td>
<td>56,758</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Government securities and other</td>
<td>849</td>
<td>849</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Equities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large cap equity</td>
<td>35,644</td>
<td>35,644</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>International equity</td>
<td>33,437</td>
<td>33,437</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Small/mid cap equity</td>
<td>22,872</td>
<td>22,872</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Commodities</td>
<td>3,665</td>
<td>3,665</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>311,596</td>
<td>311,596</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Investments reported at NAV:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multi strategy hedge funds</td>
<td>8,066</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$ 319,662</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Within the investment balance as of June 30, 2019 and June 30, 2018 are $123,297 and $89,492 restricted to Co-Pay, respectively.
LLS’s alternative investments strategy:

*Multi strategy hedge funds* – represent investments in a broad range of investment strategies that seek to exploit opportunities as they occur in the markets due to temporary dislocations or structural inefficiencies and include event driven strategies, distressed debt, merger and other arbitrage, and value investing.

This strategy creates indirect exposure to LLS through short sales of securities, trading in future and forward contracts, and other derivative products. Derivatives are investment contracts used to hedge risk. While these financial instruments may contain varying degrees of risk, LLS’s risk with respect to such transactions is limited to its capital balance in each investment.

LLS’s alternative investments contain various redemption restrictions with required written notice ranging from 45–95 days. By contrast, all of LLS’s nonalternative investments are highly liquid and can be redeemed daily without restriction. As of June 30, 2019 and 2018, the following table summarizes the redemption provisions for those investments reported at NAV:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monthly</td>
<td>$1,600</td>
<td>—</td>
</tr>
<tr>
<td>Quarterly</td>
<td>4,000</td>
<td>6,380</td>
</tr>
<tr>
<td>Semi-Annual</td>
<td>1,000</td>
<td>—</td>
</tr>
<tr>
<td>Annual</td>
<td>1,714</td>
<td>1,686</td>
</tr>
<tr>
<td>Total</td>
<td>$8,314</td>
<td>8,066</td>
</tr>
</tbody>
</table>

As of June 30, 2019 and 2018, LLS had no unfunded commitments on its alternative investments.

5) **Financial Assets**

LLS goal is to maintain financial assets to meet the requirements of all outstanding commitments, excluding Co-Pay, both current and conditional as well as a minimum of 25-50% of annual general expenditures. LLS considers all expenditures related to its ongoing mission-related activities as well as the conduct of services undertaken to support those activities to be general expenditures, excluding expenditures related to LLS Co-Pay Program. As part of LLS liquidity plan, excess cash is invested in short term investments, including money market accounts, fixed income and equities.

In addition to available financial assets, LLS operates with a balanced budget and anticipates collecting sufficient revenue to cover all general expenditures. Refer to the statement of cash flows, which identifies the sources and uses of LLS’ cash and shows positive cash generated by operations for fiscal years 2019 and 2018.
The following represents LLS’s financial assets as of June 30, 2019:

<table>
<thead>
<tr>
<th>Financial assets at year end:</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$ 24,735</td>
</tr>
<tr>
<td>Contributions and other receivable</td>
<td>15,489</td>
</tr>
<tr>
<td>Investments</td>
<td>407,903</td>
</tr>
<tr>
<td>Total financial assets</td>
<td>448,127</td>
</tr>
</tbody>
</table>

Less amounts not available to be used within one year:

<table>
<thead>
<tr>
<th>Less amounts not available to be used within one year:</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions and other receivable with donor restrictions not to be met in less than a year</td>
<td>9,485</td>
</tr>
<tr>
<td>Alternative investments with redemptions greater than 12 months</td>
<td>1,714</td>
</tr>
<tr>
<td>Equity holdings not expected to be redeemed</td>
<td>8,866</td>
</tr>
<tr>
<td>Restricted to support Co-Pay patients</td>
<td>138,538</td>
</tr>
<tr>
<td>Perpetual donor restriction</td>
<td>3,117</td>
</tr>
<tr>
<td>Total financial assets not available for use</td>
<td>161,720</td>
</tr>
</tbody>
</table>

Financial assets available to meet general expenditures within one year of the balance sheet date

$ 286,407

6) Net assets with donor restrictions

Net assets with donor restrictions and the income earned are available for the following purposes at June 30, 2019 and 2018:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$ 8,501</td>
<td>8,977</td>
</tr>
<tr>
<td>Patient and Community Service</td>
<td>4,544</td>
<td>4,609</td>
</tr>
<tr>
<td>Public Health Education</td>
<td>3,579</td>
<td>2,572</td>
</tr>
<tr>
<td>Professional Education</td>
<td>3,599</td>
<td>2,783</td>
</tr>
<tr>
<td>Beat AML Initiative</td>
<td>23,611</td>
<td>14,750</td>
</tr>
<tr>
<td>Children’s Initiative</td>
<td>2,905</td>
<td>851</td>
</tr>
<tr>
<td>Beat AML Master Trial</td>
<td>5,623</td>
<td>6,144</td>
</tr>
<tr>
<td>Co-Pay</td>
<td>43,279</td>
<td>52,528</td>
</tr>
<tr>
<td>Other</td>
<td>329</td>
<td>159</td>
</tr>
<tr>
<td>Total net assets with donor restriction</td>
<td>$ 95,970</td>
<td>93,373</td>
</tr>
</tbody>
</table>

(continues »)
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

LLS follows the provisions of the New York Prudent Management of Institutional Funds Act, which imposes guidelines on the management and investment of endowment funds. LLS has interpreted the relevant law as allowing LLS to appropriate for expenditure or accumulate so much of an endowment fund as LLS determines is prudent considering the uses, benefits, purposes, and duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument.

LLS has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while seeking to protect the original value of the gift. The spending rate policy at June 30, 2019 and 2018 was 4%, plus any additional amounts advised by donors. Under this policy, the endowment assets are invested in a manner that is intended to produce results consistent with LLS’s overall investment strategy.

The following table presents changes in the donor restricted endowment funds for the year ended June 30, 2019 and 2018:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endowment net assets at July 1</td>
<td>$6,577</td>
<td>6,282</td>
</tr>
<tr>
<td>Investment income</td>
<td>304</td>
<td>551</td>
</tr>
<tr>
<td>Foreign currency translation adjustment</td>
<td>2</td>
<td>(7)</td>
</tr>
<tr>
<td>Appropriation for expenditure</td>
<td>(303)</td>
<td>(249)</td>
</tr>
<tr>
<td>Endowment net assets at June 30</td>
<td>$6,580</td>
<td>6,577</td>
</tr>
</tbody>
</table>

7) Contribution and other receivables

LLS’s contribution and other receivables at June 30, 2019 and June 30, 2018 consist of unconditional promises to give, receivables associated with service revenue, and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met.

Contributions and other receivables consist of the following:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campaign contributions</td>
<td>$2,909</td>
<td>1,539</td>
</tr>
<tr>
<td>Other restricted contributions</td>
<td>11,627</td>
<td>15,266</td>
</tr>
<tr>
<td>Co-Pay contributions</td>
<td>—</td>
<td>15,100</td>
</tr>
<tr>
<td>Service revenue</td>
<td>953</td>
<td>350</td>
</tr>
<tr>
<td>Total</td>
<td>$15,489</td>
<td>32,255</td>
</tr>
</tbody>
</table>

(continues »)
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

Contributions receivables are originally recorded based on discounted cash flows using a risk adjusted discount rate. Amounts are scheduled to be received as follows:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than one year</td>
<td>$11,027</td>
<td>24,400</td>
</tr>
<tr>
<td>One to five years</td>
<td>6,287</td>
<td>10,076</td>
</tr>
<tr>
<td>Less:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allowance for uncollectible accounts</td>
<td>(641)</td>
<td>(987)</td>
</tr>
<tr>
<td>Discount to present value (1.5% to 5.0%)</td>
<td>(1,184)</td>
<td>(1,234)</td>
</tr>
<tr>
<td>Total</td>
<td>$17,314</td>
<td>34,476</td>
</tr>
</tbody>
</table>

As of June 30, 2019 and 2018, 39% and 77% of contributions and other receivables were from one and two funding sources, respectively.

8) Deferred Revenue

The majority of deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year end. Deferred revenue as of June 30, 2019 and 2018 consists of the following:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Special events</td>
<td>$11,782</td>
<td>12,386</td>
</tr>
<tr>
<td>Service revenue</td>
<td>1,957</td>
<td>3,857</td>
</tr>
<tr>
<td>Total</td>
<td>$13,739</td>
<td>16,243</td>
</tr>
</tbody>
</table>

9) Donated Services, Goods and Media

The value of donated goods, donated services for family support group facilitators and research grant reviewers, as well as donated media are included in both revenue and expense as shown below:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donated goods</td>
<td>$1,616</td>
<td>1,483</td>
</tr>
<tr>
<td>Donated services</td>
<td>2,924</td>
<td>2,950</td>
</tr>
<tr>
<td>Donated media</td>
<td>7,447</td>
<td>3,282</td>
</tr>
<tr>
<td>Total</td>
<td>$11,987</td>
<td>7,715</td>
</tr>
</tbody>
</table>

(continues »)
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

10) Fixed Assets, Net

Fixed assets at June 30, 2019 and 2018 consist of the following:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leasehold improvements</td>
<td>$2,577</td>
<td>$2,079</td>
</tr>
<tr>
<td>Furniture, fixtures, and other office equipment</td>
<td>4,725</td>
<td>4,154</td>
</tr>
<tr>
<td>Computer equipment and software</td>
<td>43,073</td>
<td>39,231</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>50,375</td>
<td>45,464</td>
</tr>
</tbody>
</table>

Less accumulated depreciation and amortization

<table>
<thead>
<tr>
<th>Nitrogen</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leasehold improvements</td>
<td>$2,577</td>
<td>$2,079</td>
</tr>
<tr>
<td>Furniture, fixtures, and other office equipment</td>
<td>4,725</td>
<td>4,154</td>
</tr>
<tr>
<td>Computer equipment and software</td>
<td>43,073</td>
<td>39,231</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>50,375</td>
<td>45,464</td>
</tr>
</tbody>
</table>

Less accumulated depreciation and amortization

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fixed assets, net</strong></td>
<td><strong>$ 9,161</strong></td>
<td><strong>8,614</strong></td>
</tr>
</tbody>
</table>

11) Retirement Plans

LLS has a defined contribution 403(b) plan covering all employees meeting age and service requirements. LLS contributions are based on a percentage of each eligible employee’s salary and years of service. Expenses under this plan aggregated $2,432 and $2,336 for the years ended June 30, 2019 and 2018, respectively.

LLS has nonqualified deferred compensation plans for its executive staff subject to the provisions of the Internal Revenue Code Section 457 (the 457 Plans). There were no expenses incurred for the years ended June 30, 2019 and 2018. The assets of the 457 Plans are included in investments in the accompanying consolidated balance sheet and amounted to approximately $1,747 and $1,586 at June 30, 2019 and 2018, respectively. The liabilities of the 457 Plans are included in other long term liabilities in the accompanying consolidated balance sheet and amounted to approximately $1,747 and $1,586 at June 30, 2019 and 2018, respectively.

12) Lease Commitments

The leases for premises, which LLS’s National Office and chapters occupy, expire on various dates through March 31, 2031, and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses, and utilities.

The approximate minimum aggregate future annual rental commitments are summarized as follows:

<table>
<thead>
<tr>
<th>Year ending June 30:</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
<th>Thereafter</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$8,522</td>
<td>$8,092</td>
<td>$7,395</td>
<td>$5,733</td>
<td>$3,364</td>
<td>$10,433</td>
</tr>
<tr>
<td>Total</td>
<td><strong>$43,539</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continues »)
13) Joint Costs Allocation

For the years ended June 30, 2019 and 2018, LLS incurred expenses to conduct activities that had both fundraising appeals as well as mission program and management and general components (joint activities). Those joint activities included direct mail, coinboards, and media campaigns. Such costs are allocated based on applicable accounting standards and were allocated as follows:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundraising</td>
<td>$10,150</td>
<td>7,463</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>2,978</td>
<td>3,496</td>
</tr>
<tr>
<td>Public health education</td>
<td>7,164</td>
<td>4,884</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$20,292</strong></td>
<td><strong>15,843</strong></td>
</tr>
</tbody>
</table>

14) Contingent Liabilities

LLS is a defendant in various lawsuits arising in the normal course of business. Management does not expect the ultimate resolution of these actions to have a material adverse effect on LLS’s financial position.
ACKNOWLEDGMENTS
**Research Grants**

### Specialized Center of Research

The Specialized Center of Research program funds multidisciplinary research by teams of leading-edge academic investigators that hastens the discovery and development of better treatments for leukemia, lymphoma and myeloma patients. A center is comprised of at least three independent research programs that are integrated and supported by scientific core laboratories.

- John Cleveland, PhD, 2019
  H. Lee Moffitt Cancer Center & Research Institute
- Madhav Dhodapkar, MBBS, 2020* Emory University
  Dr. Madhav Dhodapkar is jointly funded by Emory University
- Helen Heslop, MD, 2019
  Baylor College of Medicine
- Craig Jordan, PhD, 2019
  University of Colorado Denver, Anschutz Medical Campus
  Dr. Craig Jordan is jointly funded by the University of Colorado Denver, Anschutz Medical Campus
- Carl June, MD, 2020*
  The Trustees of the University of Pennsylvania, Medical Center
- Jonathan Licht, MD, 2020*
  University of Florida
- Tak Mak, PhD, 2017
  University Health Network
- Ari Melnick, MD, 2016
  Joan & Sanford I. Weill Medical College of Cornell University
  Dr. Ari Melnick is funded in part by Joan & Sanford I. Weill Medical College of Cornell University and donations from the Escher Foundation, the Jim Jacobs Foundation, the LIUNA Charitable Foundation, the Mellyner Foundation, and Angela and Gary Trotta.

- Stephen Nimer, MD, 2018
  University of Miami
  Dr. Stephen Nimer is funded in part by donations from the Sylvester Comprehensive Cancer Center of the University of Miami.
- Robert Orlowski, MD, PhD, 2018
  The University of Texas MD Anderson Cancer Center
- Andreas Strasser, PhD, FAA, MSc, 2018
  Walter & Eliza Hall Institute of Medical Research
- David Weinstock, MD, 2016
  Dana-Farber Cancer Institute
  Dr. David Weinstock is funded in part by a donation from Sandra Abbott
- Anas Younes, MD, 2017
  Sloan Kettering Institute for Cancer Research
  Dr. Anas Younes is funded in part by donations from the Jewish Federation of Cleveland, Sandi and Stan Kahan, and Cathy and Scott Zeilinger.

### Career Development Program (Scholars and Clinical Scholars)

The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, helping them devote their careers to research in leukemia, lymphoma or myeloma.

- Omar Abdel-Wahab, MD, 2017
  Sloan Kettering Institute for Cancer Research
- Arash Alizadeh, MD, PhD, 2020*
  Board of Trustees of the Leland Stanford Junior University
- Philippe Armand, MD, PhD, 2019
  Dana-Farber Cancer Institute
- Saro Armenian, DO, MPH, 2017
  Beckman Research Institute of the City of Hope
- Uttiya Basu, PhD, 2016
  The Trustees of Columbia University in the City of New York, Columbia University Medical Center
- Robert Bradley, MD, 2018
  Fred Hutchinson Cancer Research Center
  Dr. Robert Bradley is funded in part by a donation from S Lori Brown
- Jason Butler, PhD, 2019
  Hackensack Meridian Health
- Rong Lu, PhD, 2020*
  University of Southern California
  Dr. Rong Lu is jointly funded by Dana-Farber Cancer Institute.
- Alex Herrera, MD, 2019
  Beckman Research Institute of the City of Hope
  Dr. Alex Herrera is fully funded by a donation from Toni and Emmet Stephenson.
- Katherine Hsu, MD, PhD, 2017
  Sloan Kettering Institute for Cancer Research
- Keisuke Ito, MD, PhD, 2019
  Albert Einstein College of Medicine, Inc.
- Peng Ji, MD, PhD, 2018
  Northwestern University
- Hao Jiang, PhD, 2019
  University of Virginia
- Alex Kentsis, MD, PhD, 2020*
  Sloan Kettering Institute for Cancer Research
- Michael Karas, PhD, 2018
  Sloan Kettering Institute for Cancer Research
- Kasey Leger, MD, 2020*
  Seattle Children's Hospital
- Rong Lu, PhD, 2020*
  University of Southern California
  Dr. Rong Lu is jointly funded by the University of Southern California.
- Ravindra Majeti, MD, PhD, 2016
  Board of Trustees of the Leland Stanford Junior University
- Maria Figueroa, MD, 2019
  University of Miami
- Benjamin Garcia, PhD, 2016
  Perelman School of Medicine at the University of Pennsylvania
- Alfred Garfall, MD, 2020*
  Perelman School of Medicine at the University of Pennsylvania
- Ramiro Garzon, MD, 2016
  The Ohio State University
- Irene Ghobrial, MD, 2017
  Dana-Farber Cancer Institute
- David Guertin, PhD, 2016
  University of Massachusetts Medical School
- Alex Herrera, MD, 2019
  Beckman Research Institute of the City of Hope
- Carl June, MD, 2020*
  The Trustees of the University of Pennsylvania, Medical Center
- Jonathan Licht, MD, 2020*
  University of Florida
- Tak Mak, PhD, 2017
  University Health Network
- Ari Melnick, MD, 2016
  Joan & Sanford I. Weill Medical College of Cornell University
  Dr. Ari Melnick is funded in part by Joan & Sanford I. Weill Medical College of Cornell University and donations from the Escher Foundation, the Jim Jacobs Foundation, the LIUNA Charitable Foundation, the Mellyner Foundation, and Angela and Gary Trotta.

* Newly awarded or renewed grants in Fiscal Year 2020
** Grantee prematurely terminated award in Fiscal Year 2019
Shannon McKinney-Freeman, PhD, 2019
St. Jude Children’s Research Hospital

Constantine Mitsiades, MD, PhD, 2017
Dana-Farber Cancer Institute

Alison Moskowitz, MD, 2020*
Sloan Kettering Institute for Cancer Research

Ann Mullally, MD, 2018
Brigham and Women’s Hospital

Daisuke Nakada, PhD, 2020*
Baylor College of Medicine

Lakshmi Nayak, MD, 2019
Dana-Farber Cancer Institute

Trista North, PhD, 2017
Boston Children’s Hospital

Ryan O’Connell, PhD, 2018
The University of Utah

Eirini Papapetrou, MD, PhD, 2019
Icahn School of Medicine at Mount Sinai

Christopher Park, MD, PhD, 2018
New York University School of Medicine

Daniel Polyrea, MD, 2020*
University of Colorado Denver, Anschutz Medical Campus

Zhijian Qian, PhD, 2019
University of Florida

Christiane Querfeld, MD, PhD, 2019
Beckman Research Institute of the City of Hope

Dr. Christiane Querfeld is fully funded by a donation from the Schwartz Ward Family Foundation.

Kerry Rogers, MD, 2020*
The Ohio State University

Michael Savona, MD, 2019
Vanderbilt University Medical Center

Xiaobing Shi, PhD, 2017
Van Andel Research Institute

Daniel Starczynowski, PhD, 2016
Cincinnati Children’s Hospital Medical Center

Saad Usmani, MD, 2018
Atrium Health Foundation

Dr. Saad Usmani is funded in part by donations from Atrium Health Foundation.

Geoffrey Uy, MD, 2018
Washington University in St. Louis

Christopher Vakoc, MD, PhD, 2016
Cold Spring Harbor Laboratory

G. Greg Wang, PhD, 2019
The University of North Carolina at Chapel Hill

Jian Xu, PhD, 2020*
Children’s Medical Center Research Institute at UT Southwestern

Jianhua Yu, PhD, 2019
The Ohio State University/Beckman Research Institute of the City of Hope

Dr. Jianhua Yu is fully funded by a donation from the Schwartz Ward Family Foundation.

Amer Zeidman, MBBS, 2019
Yale University

Dr. Amer Zeidman is funded in part by Yale University and a donation from S Lori Brown.

Career Development Program (Special Fellows and Fellows)

Robert Albiero Gallego, PhD, 2020*
The Trustees of Columbia University in the City of New York, Columbia University Medical Center

Silvia Alvarez, PhD, 2020*
The Trustees of Columbia University in the City of New York, Columbia University Medical Center

Brandon Aubrey, PhD, 2019
Dana-Farber Cancer Institute

Will Bailis, PhD, 2019**
Yale University

Yael Ben-Nun, PhD, 2019
Dana-Farber Cancer Institute

Anat Biran, PhD, 2020*
Dana-Farber Cancer Institute

Juliette Bouyssou, PhD, 2020*
Dana-Farber Cancer Institute

George Burslem, PhD, 2018
Yale University

Chun-Chin Chen, PhD, 2020*
Joan & Sanford I. Weill Medical College of Cornell University

Pan-Yu Chen, PhD, 2019
The Regents of the University of California, San Francisco

Ryan Corces, PhD, 2018**
Board of Trustees of the Leland Stanford Junior University

Sondra Downey-Kopyscinski, PhD, 2020*
Dana-Farber Cancer Institute

Daphné Dupéré-Richer, PhD, 2019
University of Florida

Javier Garcia Bermudez, PhD, 2020*
Rockefeller University

Mitchell Geer, PhD, 2020*
New York University School of Medicine

Jennifer Grants, PhD, 2018
British Columbia Cancer Agency Branch

Zhaohui Gu, PhD, 2019
St. Jude Children’s Research Hospital

Annamaria Gulla, MD, 2020*
Dana-Farber Cancer Institute

Bingqian Guo, PhD, 2018**
Harvard Medical School

Lulu Hu, PhD, 2018
The University of Chicago

Daichi Inoue, MD, PhD, 2018
Sloan Kettering Institute for Cancer Research/Innovation at Kobe

Szuang Jiang, PhD, 2019
Board of Trustees of the Leland Stanford Junior University

Gloria Jh, PhD, 2019
Regents of the University of Michigan/The Trustees of the University of Pennsylvania, Medical Center

Emily Johnston, MD, 2019
The University of Alabama at Birmingham

Courtney Jones, PhD, 2020*
University of Colorado Denver, Anschutz Medical Campus

Niraj Joshi, PhD, 2019
Dana-Farber Cancer Institute

Vishal Khairnar, PhD, 2020*
Beckman Research Institute of the City of Hope

Richard Jason Lamontagne, PhD, 2018
The Wistar Institute

Jianping Li, MD, PhD, 2020*
University of Florida

Shan Lin, PhD, 2020*
Dana-Farber Cancer Institute

Sydney Lu, MD, PhD, 2020*
Sloan Kettering Institute for Cancer Research

Priya Mathur, PhD, 2018
The University of Chicago

Demis Menolfi, PhD, 2019
The Trustees of Columbia University in the City of New York, Columbia University Medical Center

Linde Miles, PhD, 2019
Sloan Kettering Institute for Cancer Research

Coraline Miynarczyk, PhD, 2019
Joan & Sanford I. Weill Medical College of Cornell University

Lucia Morgado-Palacin, PhD, 2018
The Trustees of Columbia University in the City of New York, Columbia University Medical Center

Tomoya Muto, MD, PhD, 2019
Cincinnati Children’s Hospital Medical Center

Tamara Ouspenskaia, PhD, 2018
Broad Institute, Inc.

Erin Peckham-Gregory, PhD, 2020*
Baylor College of Medicine

Bibiana Rius, PhD, 2019
The Scripps Research Institute

Jacqueline Rivas, PhD, 2020*
University of Kentucky

Alejo Rodriguez Fraticelli, PhD, 2019
Boston Children’s Hospital

Julia Rogers, PhD, 2020*
Harvard Medical School

Alejandro Rosman, PhD, 2020*
University of Miami

Noha Sharafeldin, MD, PhD, 2019
The University of Alabama at Birmingham

Xianguo Shi, PhD, 2020*
Sanford Burnham Prebys Medical Discovery Institute

Vipul Shukla, PhD, 2018
La Jolla Institute for Allergy and Immunology

Eric Smith, MD, PhD, 2018
Sloan Kettering Institute for Cancer Research

Dr. Eric Smith is funded in part by a donation from the Names Family Foundation.

*Newly awarded or renewed grants in Fiscal Year 2020  **Grantee prematurely terminated award in Fiscal Year 2019
Newly awarded or renewed grants in Fiscal Year 2020  
Grantee prematurely terminated award in Fiscal Year 2019

Cancer Research  
Sloan Kettering Institute for  
Akihide Yoshimi, MD, PhD, 2019  
Cancer Research  
Sloan Kettering Institute for  
Christina Yim, PhD, 2020*  
Sloan Kettering Institute for  
William Yewdell, PhD, 2019  
Anderson Cancer Center  
The University of Texas MD  
Haopeng Yang, PhD, 2020*  
Joan & Sanford I. Weill Medical College of Cornell University  
Andrew Volk, PhD, 2020*  
Northwestern University  
Ly Vu, PhD, 2019  
Sloan Kettering Institute for Cancer Research  
Adam Wilkinson, PhD, 2019  
Board of Trustees of the Leland Stanford Junior University  
Matthew Witkowski, PhD, 2018  
New York University School of Medicine  
Gongwei Wu, PhD, 2020*  
Dana-Farber Cancer Institute  
Min Xia, PhD, 2019  
Joan & Sanford I. Weill Medical College of Cornell University  
Haopeng Yang, PhD, 2020*  
The University of Texas MD Anderson Cancer Center  
William Yewdell, PhD, 2019  
Sloan Kettering Institute for Cancer Research  
Christina Yim, PhD, 2020*  
Sloan Kettering Institute for Cancer Research  
Akihide Yoshimi, MD, PhD, 2019  
Sloan Kettering Institute for Cancer Research  
Noemi Zambetti, PhD, 2018  
The Regents of the University of California, San Francisco  
Jiajun Zhu, PhD, 2018  
Sloan Kettering Institute for Cancer Research  
Translational Research Program  
The Translational Research Program supports outstanding investigators deemed by our expert advisors most likely to translate basic biomedical discoveries into new, safe and effective treatments, ultimately prolonging and enhancing patients’ lives.  
Iannis Afantis, PhD, 2020*  
New York University School of Medicine  
Carl Allen, MD, PhD, 2018  
Baylor College of Medicine  
Stephen Ansell, MD, PhD, 2018  
Mayo Clinic, Rochester  
Dr. Stephen Ansell is funded in part by a donation from the Albrecht Family.  
Scott Armstrong, MD, PhD, 2020*  
Dana-Farber Cancer Institute  
Fotis Asimakopoulou, MD, PhD, 2018  
The Board of Regents of the University of Wisconsin System  
Dr. Fotis Asimakopoulou is funded in part by a donation from the Greater Milwaukee Foundation.  
Jon Aster, MD, PhD, 2018  
Brigham and Women’s Hospital  
Brian Baker, PhD, 2020*  
University of Notre Dame  
Venkata Lokesh Battula, PhD, 2020*  
The University of Texas MD Anderson Cancer Center  
Smita Bhatia, MD, MPH, 2019  
The University of Alabama at Birmingham  
Ranjit Bindra, MD, PhD, 2018  
Yale University  
Bruce Blazar, MD, 2018  
University of Minnesota, Twin Cities  
Patrick Brown, MD, 2020*  
The Johns Hopkins University School of Medicine  
Dr. Patrick Brown is jointly funded by Amgen, Inc.

*Newly awarded or renewed grants in Fiscal Year 2020  **Grantee prematurely terminated award in Fiscal Year 2019
The New Idea Award is a concept award that funds innovative approaches that may fundamentally change the understanding, diagnosis and/or treatment of blood cancers and related premalignant conditions. 
Mark Cobbold, MD, PhD, 2019 Massachusetts General Hospital

MPN Challenge Grants
This program is run in partnership with the MPN Research Foundation.
Matyas Ecsedi, MD, PhD, 2020* Fred Hutchinson Cancer Research Center
Yelena Ginsburg, MD, 2020* Icahn School of Medicine at Mount Sinai
Vikas Gupta, MD, 2020* Princess Margaret Cancer Center, University Health Network
Catriona Jamieson, MD, PhD, 2020* The Regents of the University of California, San Diego
Alison Moliterno, MD, 2020* The Johns Hopkins University School of Medicine
Jyoti Nangalia, PhD, 2020* Wellcome Trust Sanger Institute
Vijay Sankaran, MD, PhD, 2020* Boston Children’s Hospital

Screen to Lead Program
The Screen to Lead Program offers drug discovery support specifically directed towards medicinal chemistry and/or drug target screening in hematological malignancies.
Jolanta Grembecka, PhD, 2020* Regents of the University of Michigan
John Sondek, PhD, 2020* The University of North Carolina at Chapel Hill

Translational Research Program: Renewal
Katherine Borden, PhD, 2020* Institute for Research in Immunology and Cancer
Leandro Cerchietti, MD, 2019 Joan & Sanford I. Weill Medical College of Cornell University
Dr. Leonardo Cerchietti is funded in part by a donation from Jace Elinson/Charlotte Meyers Endowment Fund.
Mignon Loh, MD, 2019 The Regens of the University of California, San Francisco
Feyruz Rassool, PhD, 2019 University of Maryland at Baltimore

*Newly awarded or renewed grants in Fiscal Year 2020  **Grantee prematurely terminated award in Fiscal Year 2019

Charles Mullighan, MD, 2020* St. Jude Children’s Research Hospital
Dr. Charles Mullighan is jointly funded by Snowdome Foundation and Leukaemia Foundation of Australia.
Ryotaro Nakamura, MD, 2020* Beckman Research Institute of the City of Hope
Dr. Ryotaro Nakamura is jointly funded by Beckman Research Institute of the City of Hope.
Sattva Neelapu, MD, 2020* The University of Texas MD Anderson Cancer Center
Stephen Nimer, MD, 2018 University of Miami
Dr. Stephen Nimer is funded in part by donations from The Babich Family Foundation.
Stephen Nott, PhD, 2020* Walter & Eliza Hall Institute of Medical Research
Dr. Stephen Nott is jointly funded by Snowdome Foundation and Leukaemia Foundation of Australia.
Owen O’Connor, MD, PhD, 2020* The Trustees of Columbia University in the City of New York, Columbia University Medical Center
Dr. Owen O’Connor is jointly funded by The Trustees of Columbia University in the City of New York, Columbia University Medical Center.
Jae Park, MD, 2018 Sloan Kettering Institute for Cancer Research
Dr. Joe Park is funded in part by donations from Edith Klein, the Hairy Cell Leukemia Foundation, and The SASS Foundation for Medical Research, Inc.
Laura Pasqualucci, MD, 2019 The Trustees of Columbia University in the City of New York - Morningside
Joel Pomerantz, PhD, 2020* The Johns Hopkins University School of Medicine
Sean Post, PhD, 2019 The University of Texas MD Anderson Cancer Center
Jun Qi, PhD, 2018 Dana-Farber Cancer Institute
Katy Rezvani, MD, PhD, 2018 The University of Texas MD Anderson Cancer Center
Rizwan Romee, MD, 2020* Dana-Farber Cancer Institute
Steven Rosen, MD, 2019 Beckman Research Institute of the City of Hope
Davide Rossi, MD, PhD, 2020* Foundation for the Institute of Oncology Research
Michael Rout, PhD, 2020* Rockefeller University
Kathleen Sakamoto, MD, PhD, 2020* Board of Trustees of the Leland Stanford Junior University
Deeppa Sampath, MD, PhD, 2018 The Ohio State University
Guy Sauvageau, MD, PhD, FRCPC, 2018 Institute for Research in Immunology and Cancer
Dr. Guy Sauvageau is funded in part by donations from The Babich Family Foundation.
Barbara Savoldo, MD, PhD, 2018 The University of North Carolina at Chapel Hill
Mala Shanmugam, PhD, 2019 Emory University
Kevin Shannon, MD, 2020* The Regents of the University of California, San Francisco
Dr. Kevin Shannon is jointly funded by The Regents of the University of California, San Francisco.
Aditi Shastril, MD, 2020* Montefiore Medical Center
Margaret Shipp, MD, 2020* Dana-Farber Cancer Institute
Lev Silberstein, MD, PhD, 2018 Fred Hutchinson Cancer Research Center
Tomasz Skorski, MD, PhD, DSc, 2019 Temple University
Karin Tarte, PhD, 2020* National Institute of Health and Medical Research
Enrico Tiacci, MD, 2018 University of Perugia
Dr. Enrico Tiacci is funded in part by donations from Edith Klein, the Hairy Cell Leukemia Foundation, and The SASS Foundation for Medical Research, Inc.
Wei Tong, PhD, 2018 The Children’s Hospital of Philadelphia
Ashwin Unnikrishnan, PhD, 2020* The University of New South Wales
Dr. Ashwin Unnikrishnan is jointly funded by Snowdome Foundation and Leukaemia Foundation of Australia.
Amit Verma, MD, 2019 Albert Einstein College of Medicine, Inc.
Dan Vogl, MD, 2020* The Trustees of the University of Pennsylvania, Medical Center
Loren Walensky, MD, PhD, 2020* Dana-Farber Cancer Institute
Dr. Loren Walensky is funded in part by a donation from Lisa and James Lafore.
Brian Walker, PhD, 2020* University of Arkansas for Medical Sciences
Kirsten Williams, MD, 2019 Children’s Research Institute
Dr. Kirsten Williams is funded in part by a donation from The Holland C. Gregg IV Research Fund.
Kai Wucherpfennig, MD, PhD, 2019 Dana-Farber Cancer Institute
Andrew Zannettino, PhD, 2020* University of Adelaide
Fenghuang Zhan, MD, PhD, 2018 The University of Iowa
Baochun Zhang, MD, PhD, 2020* Dana-Farber Cancer Institute

Aaron Schimmer, MD, PhD, 2020* Princess Margaret Cancer Center, University Health Network

*Newly awarded or renewed grants in Fiscal Year 2020  **Grantee prematurely terminated award in Fiscal Year 2019

ANNUAL REPORT 2019 61
IWMF Grants
This program is run in partnership with the International Waldenstrom's Macroglobulinemia Foundation.

Yong Li, PhD, 2020*
Cleveland Clinic Foundation
Constantine Mitsiades, MD, PhD, 2020*
Dana-Farber Cancer Institute
Marcel Spaargaren, PhD, 2020*
Academic Medical Center Amsterdam

Rising Tide Foundation for Clinical Cancer Research/LLS Patient-Focused Prevention Grants for Blood Cancer
This program is run in partnership to advance breakthroughs in the prevention of blood cancers.

C. Ola Landgren, MD, PhD, 2019
Sloan Kettering Institute for Cancer Research
Dr. C. Ola Landgren is funded in part by a donation from Wrobel Family Foundation.
Liran Shlush, MD, PhD, 2019
Weizmann Institute of Science
Dr. Liran Shlush is funded in part by a donation from Wrobel Family Foundation.
George Vassiliou, MD, PhD 2019
Wellcome Trust Sanger Institute
Dr. George Vassiliou is funded in part by a donation from Wrobel Family Foundation.

Mantle Cell Lymphoma Research Initiative
The Mantle Cell Lymphoma Research Initiative supports teams of researchers representing different disciplines and engaging in collaborative efforts to discover new approaches to treat patients with blood cancers.

Selina Chen-Kiang, PhD, 2019
Joan & Sanford I. Weill Medical College of Cornell University
Dr. Selina Chen-Kiang is funded in part by donations from Steven M. Durham and The Sarah Cannon Fund at the HCA Foundation.
Larry Kwak, MD, PhD 2019
Beckman Research Institute of the City of Hope
Dr. Larry Kwak is funded in part by donations from Steven M. Durham and The Sarah Cannon Fund at the HCA Foundation.

PedAL
LLS PedAL is a global precision medicine master clinical trial that will test multiple targeted therapies for relapsed acute leukemia simultaneously at up to 200 clinical sites worldwide. We are setting the groundwork for LLS PedAL throughout 2019, with the goal of treating the first patient in the summer of 2020.

Todd Cooper, DO, 2020*
Seattle Children’s Hospital
E. Anders Kolb, MD, 2020*
Nemours Alfred I. duPont Hospital for Children
Samuel Voichenboium, MD, PhD, 2020*
The University of Chicago

Special Initiatives
Peter Adamson, MD, 2019
The Children’s Hospital of Philadelphia
Dr. Peter Adamson is funded in part by a donation from Bayer Healthcare Pharmaceuticals.
Carma Bylund, PhD, 2020*
University of Florida
Dr. Carma Bylund is funded in part by a donation from the Carolan Research Institute.
Rena Corti, PhD, 2019
The University of Chicago
Amy Davidoff, PhD, 2020*
Yale University School of Medicine
Stacie Dusetzina, PhD, 2020*
Vanderbilt University Medical Center
Oliver Jonas, PhD, 2020*
Brigham and Women’s Hospital
Dr. Oliver Jonas is funded in part by a donation from Dr. Ralph & Marian Falk Medical Research Trust.
E. Anders Kolb, MD, 2019
Nemours Alfred I. duPont Hospital for Children
Dr. E. Anders Kolb is funded in part by a donation from Bayer Healthcare Pharmaceuticals.
Soheil Meshinchi, MD, PhD, 2019
Fred Hutchinson Cancer Research Center
Dr. Soheil Meshinchi is funded in part by a donation from Bayer Healthcare Pharmaceuticals.
Markus Muschen, MD, PhD, 2020*
Beckman Research Institute of the City of Hope
Dr. Markus Muschen is funded in part by a donation from Dr. Ralph & Marian Falk Medical Research Trust.
Susan Parsons, MD, 2020*
Tufts Medical Center
David Teachey, MD, 2019
The Children’s Hospital of Philadelphia
Dr. David Teachey is jointly funded by The Children’s Hospital of Philadelphia.

*Newly awarded or renewed grants in Fiscal Year 2020  **Grantee prematurely terminated award in Fiscal Year 2019
Partnerships

Therapy Acceleration Program Partnerships

Biotechnology Partners
Acetylon Pharmaceuticals, Inc.
Boston, MA
Affimed Therapeutics AG
Heidelberg, Germany
Constellation Pharmaceuticals, Inc.
Cambridge, MA
Decoy Biosciences, Inc.
San Diego, CA
Forty Seven, Inc.
Menlo Park, CA
ImmunGene, Inc.
Camarillo, CA

Academia Partners
KDAC Therapeutics, Inc.
Cambridge, MA
Kiadis Pharma NV
Amsterdam, Netherlands
miRagen Therapeutics, Inc. *
Boulder, CO
NexImmune, Inc.
Gaithersburg, MD
OncoPep, Inc.
North Andover, MA
Ryvu Therapeutics SA
Krakow, Poland
Stemline Therapeutics, Inc.
New York, NY
Sutro Biopharma, Inc.
San Francisco, CA
Travera, LLC
Cambridge, MA
Verastem Oncology
Needham, MA
X4 Pharmaceuticals, Inc. **
Cambridge, MA

* Equity investment of $1,000,000 in Fiscal Year 2019
** Equity investment of $3,300,000 in Fiscal Year 2019

Advisors

Medical & Scientific Affairs Committee

Steven Rosen, MD, FACP
Beckman Research Institute of the City of Hope
Chair
Stephen Ansell, MD, PhD
Mayo Clinic, Rochester
P. Leif Bergsagel, MD
Mayo Clinic, Arizona
Ravi Bhatia, MD
The University of Alabama at Birmingham
Catherine Bollard, MD, MBCB
Children’s Research Institute
S. Lori Brown, PhD, MPH
Former U.S. Food & Drug Administration
Renzo Canetta, MD
Former Bristol-Myers Squibb
Giulio Draetta, MD, PhD
The University of Texas MD Anderson Cancer Center
Christopher Flowers, MD
The University of Texas MD Anderson Cancer Center
Janice Gabrilove, MD
Icahn School of Medicine at Mount Sinai
Irene Ghobrial, MD
Dana-Farber Cancer Institute
Larry Kwak, MD, PhD
Beckman Research Institute of the City of Hope
Michelle LeBeau, PhD
The University of Chicago
Ross Levine, MD
Sloan Kettering Institute for Cancer Research

Jonathan D. Licht, MD
University of Florida
Ruben Mesa, MD
The University of Texas Health Science Center at San Antonio
Susan M. O’Brien, MD
The Regents of the University of California, Irvine
David Weinstock, MD
Dana-Farber Cancer Institute

Therapy Acceleration Program Committee

Co-Chairs
Dana Callow, MBA
Boston Millennia Partners
C. Casey Cunningham, MD
Santé Ventures

Members
William S. Dalton, MD, PhD
M2Gen
Giulio Draetta, MD, PhD
The University of Texas MD Anderson Cancer Center
Christopher Flowers, MD
The University of Texas MD Anderson Cancer Center
Laura S. Kaufman, PhD, DABT
Private Consultant
Ross L. Levine, MD 1
Sloan Kettering Institute for Cancer Research
Ronald Levy, MD
The Board of Trustees of the Leland Stanford Junior University
Vern Norvell, JD
Wilson Santini Goodrich & Rosati
Susan M. O’Brien, MD
The Regents of the University of California, Irvine

Robert J. Rosen, JD
Greyhawk Capital Advisors
Steven T. Rosen, MD, FACP
Beckman Research Institute of the City of Hope
David Weinstock, MD 2
Dana-Farber Cancer Institute

1 ended service in January 2019
2 started service in January 2019
We are pleased to recognize the extraordinary involvement of individuals, companies, corporations and organizations in their support of LLS and its mission. Those honored give of their time, talent and treasury and have made a significant difference in the lives of so many. To find out more about our awards program, please go to http://www.LLS.org/national-awards-nomination.

Congratulations to all the 2019 awardees!

National Recognition & Awards Recipients

President’s Award
This award recognizes a volunteer whose personal commitment and dedication inspires and motivates others to support our mission.
Charles Esten & Family
Tennessee Chapter

Robert de Villiers Spiral of Life Award
This award honors the memory of Robert de Villiers whose parents Rudolph and Antoinette de Villiers founded a foundation that is now known as The Leukemia & Lymphoma Society.

The award recognizes an individual who through their leadership and tireless effort to raise funds and influence policy has advanced the mission of LLS.
Tom Philbrick, MD
Georgia Chapter
Robert (Bob) Dean
Greater Sacramento Area Chapter
Dr. Jerry Adams
Australia

Vision for Life Award
This award recognizes an individual, corporation or organization whose ability to think outside of the box has helped to create a new fundraising campaign/program or has enhanced an existing event that has national potential.
Amanda Tiede
National Capital Area Chapter
Colton’s Army
Washington/Alaska Chapter

Advocacy Award
This award recognizes the commitment and dedication of individuals who support the Office of Public Policy initiatives.
William Teator
Upstate New York/Vermont Chapter

Leadership Award
This award recognizes an individual who has been active in a chapter for at least three years and has provided expertise and guidance that have helped the chapter achieve new levels of success.
Gregg & Karen Ritchie
California Southland Chapter
Scott Jackson
Eastern Pennsylvania Chapter
Bill Rawlings
Georgia Chapter
K.Sue Duncan
Greater Bay Area Chapter
Roland Guillen
Greater Sacramento Area Chapter
Carmen Cruz
Long Island Chapter
Robert and Jenny Katler
Mississippi/Louisiana Chapter
Tom Davis
North Carolina Chapter
Miller Paint
Oregon SW Washington Idaho Montana Chapter
Ronda Conger
Oregon SW Washington Idaho Montana Chapter
Sam Forrest
Palm Beach/Treasure Coast Chapter
Bryan Austin
Rocky Mountain Chapter
Enerplus Resources (USA) Corporation
Rocky Mountain Chapter
Heath Melton
Texas Gulf Coast Chapter
Jim Carman
Texas Gulf Coast Chapter
Marshall Esler
Tri-State Southern Ohio Chapter
Eric Davis
Tri-State Southern Ohio Chapter
AJ Boddien
Upstate New York/Vermont Chapter
Bill Torney
Virginia Chapter
Jason Mascitti
Wisconsin Chapter

Quality of Life Award
This award recognizes a member of the medical community, a social worker, or a caregiver, who has provided outstanding support, counsel or guidance to blood cancer patients or their families.
John M. Timmerman, MD
California Southland Chapter
Neal Rosen
Greater Bay Area Chapter
Dulcy Wilson
Greater Sacramento Area Chapter
Jamie McDonald, LCSW
New Mexico Chapter
Kathryn Kolibaba, MD
Compass Oncology
Oregon SW Washington Idaho Montana Chapter
Jack Aiello
Silicon Valley & Monterey Bay Area Chapter

Larry Nielsen
Upstate New York/Vermont Chapter
Dr. Scott Kruger
Virginia Chapter
Dr. Richard Hansen
Wisconsin Chapter

Special Recognition Award
This award recognizes an individual who is deserving of recognition for their outstanding commitment to an event or program that has resulted in increasing revenue and building public awareness of LLS.
TGI Fridays - The Briad Group
California Southland Chapter
Gregg Metcalf
Georgia Chapter
Caitlin Grace
Greater Bay Area Chapter
Arielle Garcia
Greater Sacramento Area Chapter
David Mutnick
Illinois Chapter
Brenda McCarthy
Long Island Chapter
Marc and Shari Weissbach
Long Island Chapter
Jennifer Oz
Orange County Inland Empire Chapter
I Choose Joy
Oregon SW Washington Idaho Montana Chapter
Katlin Cauffman
Oregon SW Washington Idaho Montana Chapter
Paige McCoy
Rocky Mountain Chapter
Ron Cohn
San Diego Chapter
Dr. Grenita Lathan
Texas Gulf Coast Chapter
Elizabeth Jordan
Texas Gulf Coast Chapter
Howard Hughes Corporation
Texas Gulf Coast Chapter
Media Awards Recipients

Recipients have a record of excellence in fundraising and promotional support, as well as educating and informing the public of LLS and its mission.

Digital Media
Clear Channel Outdoor
Minnesota Chapter
Brew Creative Media
Minnesota Chapter

Print Journalism
Comstock's Magazine
Greater Sacramento Area Chapter
The Modesto Bee
Greater Sacramento Area Chapter
Cancer Wellness Magazine
Illinois Chapter

Radio
Nick McLlwa
Preston & Steve Show
Eastern Pennsylvania Chapter
WMMR 93.3
Preston & Steve Show
Eastern Pennsylvania Chapter
Hubbard Radio
Gateway Chapter
Cumulus Radio Station
Group in Minneapolis
Minnesota Chapter
Hubbard Radio
WIRK, WRMF
Palm Beach/Treasure Coast Chapter
Melanie Rutledge
KOOL 105
Rocky Mountain Chapter
KOOL 105
Rocky Mountain Chapter
104.5 The Zone
Tennessee Chapter
Sunny 991
Texas Gulf Coast Chapter
iHeartMedia - Seattle
Washington/Alaska Chapter

Television
KMOV St. Louis
Gateway Chapter
Toni Valliere
KCRA 3
Greater Sacramento Area Chapter

Print Journalism
Comstock’s Magazine
Greater Sacramento Area Chapter
The Modesto Bee
Greater Sacramento Area Chapter
Cancer Wellness Magazine
Illinois Chapter
Chris Ohmer
Cincinnati Magazine
Tri-State Southern Ohio Chapter
Cincinnati Magazine
Tri-State Southern Ohio Chapter

Radio
Nick McLlwa
Preston & Steve Show
Eastern Pennsylvania Chapter
WMMR 93.3
Preston & Steve Show
Eastern Pennsylvania Chapter
Hubbard Radio
Gateway Chapter
Cumulus Radio Station
Group in Minneapolis
Minnesota Chapter
Hubbard Radio
WIRK, WRMF
Palm Beach/Treasure Coast Chapter
Melanie Rutledge
KOOL 105
Rocky Mountain Chapter
KOOL 105
Rocky Mountain Chapter
104.5 The Zone
Tennessee Chapter
Sunny 991
Texas Gulf Coast Chapter
iHeartMedia - Seattle
Washington/Alaska Chapter

Television
KMOV St. Louis
Gateway Chapter
Toni Valliere
KCRA 3
Greater Sacramento Area Chapter

Print Journalism
Comstock’s Magazine
Greater Sacramento Area Chapter
The Modesto Bee
Greater Sacramento Area Chapter
Cancer Wellness Magazine
Illinois Chapter
Chris Ohmer
Cincinnati Magazine
Tri-State Southern Ohio Chapter
Cincinnati Magazine
Tri-State Southern Ohio Chapter

Radio
Nick McLlwa
Preston & Steve Show
Eastern Pennsylvania Chapter
WMMR 93.3
Preston & Steve Show
Eastern Pennsylvania Chapter
Hubbard Radio
Gateway Chapter
Cumulus Radio Station
Group in Minneapolis
Minnesota Chapter
Hubbard Radio
WIRK, WRMF
Palm Beach/Treasure Coast Chapter
Melanie Rutledge
KOOL 105
Rocky Mountain Chapter
KOOL 105
Rocky Mountain Chapter
104.5 The Zone
Tennessee Chapter
Sunny 991
Texas Gulf Coast Chapter
iHeartMedia - Seattle
Washington/Alaska Chapter
Donors

We gratefully acknowledge the individuals, foundations and corporations that generously supported LLS’s mission during this fiscal year.

**Leadership Circle**

**$500,000-$999,999**

- AbbVie Inc.
- Amgen Inc.
- Astellas Pharma US, Inc.
- Bloomberg Philanthropies
- Carolan Research Institute*
- Don & Lorraine Freeberg Foundation
- Kite, A Gilead Company
- Lang / Stiglitz Family Fund
- Katherine and James Lau*
- Leukaemia Foundation*
- MUY Hamburger Partners LLC
- The Norcross Foundation, Inc. In Memory of Herrick F. Norcross, Jr. (Rick)*
- Novartis Pharmaceuticals PA
- Lynne and Greg O'Brien*
- Salesforce
- Snowdome Foundation*
- Toni and Emmet Stephenson*

**$100,000-$249,999**

- Albert & Elaine Borchard Foundation
- The Alice Lawrence Foundation
- Alto-Shaam, Inc.
- Anna and Dean Backer*
- Black Dog Charity
- Bloomberg
- William and Tamea Bock
- Cal Turner Family Foundation*
- Celebrity Cruises
- The Charles Engelhard Foundation*
- Lisa Norcia Cheskin and Barry Cheskin*
- The Chicago Community Foundation
- Cleveland Clinic
- Michael and Liz Copley*
- Custom Ink
- Daiichi Sankyo
- Robert and Cindy Dickinson
- John and Ann Doerr
- Earl D. and Marian N. Olson Fund
- The Edward J. Phillips Family Foundation*
- Enmark Stations, Inc.
- F. M. Kirby Foundation, Inc.
- Chiyoko Furukawa*
- Greater Milwaukee Foundation, Inc.*
- The Hairy Cell Leukemia Foundation*
- The Hearst Foundation
- Higgins Family Charitable Foundation
- Incyte Corporation
- The J.T. Tai & Co. Foundation, Inc.
- William and Jennifer Kenneally*
- The Laborers Charitable Foundation
- Joyce and Larry Lacerte*
- Paul Leinwand
- Jeannie and Steve Lieblich*
- Cristine and Timothy Lindenfelser
- Mable Hamann Revocable Trust
- Clyde McGregor and LeeAnn Pederson Pope
- Melissa Reasner McGuire Advised Endowment Fund
- Memorial Cancer Institute
- Melovee White Trust Alice L Clare Trustee
- Nike, Inc.
- NSC Global
- Rick Ostroff*
- Pennsylvania Department of Health Pressio
- PSEG Foundation
- PWC
- Rahr Corporation*
- Pat and Jeff Sachs*
- The SASS Foundation for Medical Research, Inc.*
- Jeff Schoepfel
- Michael Scotece
- Silicon Valley Bank
- Stanford Children’s Health
- Stifel
- Sylvester Comprehensive Cancer Center, University of Miami
- Teva Pharmaceuticals
- Gary and Angela Trovato*
- TrueNorth Energy
- UCLA Health
- VyStar Credit Union
- West Marine
- Wrobel Family Foundation
- Roger Zacher
- Anonymous (4 donors)

**Pharmaceutical Funding Legend**

- Patient Access
- Public Policy
- Research
- Campaign

* Denotes multi-year commitment

**President’s Circle**

**$1,000,000 and Above**

- Monica and Timothy Babich*
- Jeff Binder
- Burlington
- Celgene Corporation
- Cynthia and Frank Gasztory*
- Dr. Ralph & Marian Falk Medical Research Trust*
- Genentech/Biogen
- Gilead Sciences, Inc.
- The Harry T. Mangurian Jr. Foundation, Inc.*
- Jazz Pharmaceuticals, Inc.
- LIUNA Charitable Foundation*
- The Lyon Family Foundation*
- Pharmacyclics/Janssen
- Donald Porteous*
- Joan and Paul Rubschlager*
- The Sarah Cannon Fund at the HCA Foundation*
- Schwartz Ward Foundation*
- Subaru of America Inc.
- Takeda Oncology
- UFCW
- Walgreens
- The Wawa Foundation
- Anonymous (1 donor)
Discovery Circle
$50,000-$99,999

27th Investments LLC
ADP
Agios Pharmaceuticals, Inc.
Akin Gump Strauss Hauer & Feld, LLP
Allegheny Foundation
ArcherDX
Avella Specialty Pharmacy
The Batchelor Foundation, Inc.
BDO USA LLP
Blue Lagoon Foundation
BlueCross BlueShield of Alabama
Bob Moore Subaru
Boscov’s Home Office
CareFirst BlueCross BlueShield
Vanessa and Mark Cereceda
The Chelsea Morrison Foundation
Compass Self-Storage, LLC
Dan and JoAnne Coolidge
D.M. Foundation
DC’S Dancing Stars Gala
Deseret Trust Company
Don Mealey Subaru Sport Ecolab
Elbit System of America
Elevation Church
Enery Texas
Gary and Susan Farmer
John Fitch
FIS
Flamingo Inc.
Florida Cancer Specialists
Freeman Expositions, LLC
Garden City Turkey Trot
The Gaughen Management Group
Geico
Generac Power Systems, Inc.
Georgia Power Company
Hannig Law
Harold Salmanowitz Charitable Lead Trust
Dan Harrington
The Hatton Foundation
Marianne Heatherly
Heritage Title
Hildegarde D. Becher Foundation Inc.
HM Insurance Group
Howard Family Foundation
John and Kristin Hyland
IBERIABANK
Ice Mobility Foundation
Imagine a Cure for Leukemia
Iron Bow Technologies
Jackson Family Fund
JAE Restaurant Group
Janssen Biotech
The Jerry C. Dearing Family Foundation
JLL
The John and Frances Beck Family Foundation
Johnson & Johnson
Joseph Kelley
Keystone Holdings
Kindred Healthcare Operating, Inc.
Kingsbury Family Fund
Koppers, Inc.
KPMG
Krispy Kunchy Foods, LLC
L & R Structural Corp.
Lanphere Auto Group
Lehigh Valley Restaurant Group, Inc.
Red Robin
Lighthouse Partner
Judy and Charlie Lynch
Maine Cancer Foundation
Joe Maio
McKesson Specialty Health
Medical Properties Trust
Corinne and Jon Merksamer
Miami Cancer Foundation
Montgall Scholarship Fund, Inc.
The Moorings
Nancy Nasher and David Hameseger
The Nashville Wine Auction
Chris Neibauer
Nimick Forbesway Foundation
Norwegian Cruise Line
Lindsey Noto
Opal Wealth Advisors
Ostroff Associates
Kaylene and Rajiv Patel
Pieper Electric, Inc.
The Ping Y. Tai Foundation, Inc.
PinkTie.org
Pizza Hut of America, Inc.
Planned Systems International
PNC Bank
Fred and Cherie Pond
PRA Health Sciences
Dr. George Rapier
Barbara and Brent Reid
Robert E. Gallagher Charitable Trust
Melody and Rick Rogers
Lois and Jerry Rosenblum
Sagepoint Financial, Inc.
Stacy Sager
SagerStrong Foundation Inc.
SAIC
Salt River Pima-Maricopa Indian Community (SRPMIC)
Neil Salvage
Serber Charitable Trust
Seattle Genetics
Sempra Energy
Mr. and Mrs. Richard Smith
Snap Crack Chiropractic
Margaret and Donald Steiner
Summit1G
Survivor Spotlight
Mark Taylor
Thrivent Choice Wisconsin
United Way of San Antonio and Bexar County
Verizon
VGM Associates Ltd.
The Victor E. & Caroline E. Schutte Foundation
The Walt Disney Company
The Ward Law Group
Wells Fargo
Wendmiddle LLC
West Pharmaceutical Services, Inc.
Wilhelm Restaurant Group, Inc.
Anonymous (2 donors)

$25,000-$49,999

1889 Foundation
7 Eleven, Inc.
Jim Abedi
ABM Industries
Kenneth Aboussie
Advent Health
The Alice Lawrence Foundation, Inc.
Alston Construction
Alverin M. Cornell Foundation
AM Charity Fund
Ameren Missouri
ANF Group
Michael Arougheti
Arthur M. Blank Family Foundation
Assemi Group, Inc.
Assurance Power Systems
Astex Pharmaceuticals, Inc.
AT&T
The Aurora Highlands
AutoNation Subaru Hunt Valley
Bank of America
Joseph Baratta
Barclays Bank Delaware
Barings
Traci and Tedd Barr
Baylor Scott & White
BeiGene, Ltd
Beil
Berkshire Bank
Biologics By McKesson
Bireley Family Foundation
Blackbaud
Andrew and Danielle Blass
BlueCross BlueShield of South Carolina
Ed and Susan Blumenfeld
Bobby & Steve’s Auto World
Youth Foundation
Ron Secours St Francis
Brayton Purcell, LLP
Briggs Equipment
JD Brooks
Jeff and Becky Burch
The C. Kenneth & Laura Baxter Foundation
Jack Callon
Camelback Subaru
Cancer Treatment Centers of America Global Inc.
Carlos Batista Foundation
Carlson Family Foundation, Inc.
Charles and Chris Carroll
Carz Cruizin Inc.
CBRE Group
Cedar Fair Charities
Centene Corporation
Certainty Home Loans
Kapania Chakraburty
Charles McMurray Co.
Chemed Foundation
Chicago Title
Chickasaw Nation
Children’s Mercy Hospital
Circle City Foundation
Cit Group Foundation
Citrix
CityWorth
CNA
Ron and Guadalupe Cohn Communities Foundation of Texas
Community Foundation
Sonoma County

ANNUAL REPORT 2019 67
SuperValu Inc.
Sutter Health
Suvoda
Michael Sweig
Target CW
TECO Energy
Terumo BCT
Texas Instruments, Inc.
Thunderbirds Charities
Tigerfight Foundation
Tidten-Coil Constructors Team KSmo
Todd Reed McClintock
Research Foundation
Tolero Pharmaceuticals, Inc.
C
Tour de Court 2019
Travel Leaders Group
Trevor Loughlin Foundation Inc.
True North Studio
Ultimate Software
UNC REX Healthcare
United Way of Greater Milwaukee & Waukesha County, Inc.
UnitedHealthcare
The University of Kansas Cancer Center
University of Michigan Rogel Cancer Center
The University of Texas MD Anderson Cancer Center
UPMC
Valero
Valley Children’s Hospital
Larinda Van Groningen
VCU Health System
Venable LLP
Judith Von Seldeneck
Wafra Inc.
Washington Gas Light Federal Credit Union
Greg Weimer
Ellen Weissberg
Gloria Weissberg
Mark Weissberg
Wellmed Charitable Foundation
Wespac Construction Inc.
Wet Willie’s Management Corp.
William R. Rich Foundation
James and Judy Wilson
WisC Enterprises
Anonymous (5 donors)

$10,000-$24,999

101 Surf Sports
43rd Annual Amusement Theme Park Conference
60Feet6 Foundation
Abacus Technical Services, LLC
The Abatecola Foundation
Bruce Abbey
Sandy Abbott
Linda and Tim Abell
Accel
Accelerated Urgent Care
Access Capital Foundation
Accord Healthcare, Inc.
ACE Family Foundation
Acertitude
Ann Adams
Susan Adams
Michael Adams
Adaptive Biotechnologies
Adonel Concrete
Advance Auto Parts
Advanced Computer Concepts
Aerotek
Aetna
Allac
Against the Storm Foundation
Greg Ager and Dave Dolan
AIG
Alaska Airlines Matching Program
Michael and Melissa Aber
The Albrecht family
Alexandria Real Estate Equities, Inc.
Alibaba Group
Allegion
Adam Allen
Pat and Debbie Allender
Alliance RX Walgreens Prime
Alliant Insurance Services
Allied Associates International
Allmond & Company, LLC
Amadeus North America, Inc.
AmCap Mortgage, LTD
Amerant Bank
American Ambulance
American Punjabi Charity
Golf Association
AMERICAN SYSTEMS
Ames Construction
Ami Onco Theranostics
Anadarko
Anaheim Ducks Foundation, Inc.
Dwight Anderson
Jean and C.E. Andrews
Anne Wilson
ANRAK Corporation
Ansira
Anthem
Anthem Blue Cross
AON Corporation
Aon Risk Services
Apex Foundation
Apple
Arizona Public Service
APTO Solutions
Aptose Biosciences
Margaret Arakawa
Arch-Con Corporation
Steve Armstrong
Phillip Armstrong
Arnoff Kearns Family Foundation
Donor Advised Fund
Ascend Learning LLC
Ascension
Associated Credit Union
Assurant
Astellas
Asuragen, Inc.
The Atlanta Foundation
Atlantic Health System
Austin Hardware & Supply
Authentic
Avalere Health
AvalonBay Communities, Inc.
Avantos Sciences Foundation
Aventri
Avery
Avison Young USA Inc.
Baker Botts
Baker Hughes Foundation
Baltimore Orioles
BankSouth Mortgage
Banner MD Anderson
The Bar LV
The Barbara and William Rosenthal Family Foundation
Dr. and Mrs. William Barfield
Maggy Barnaba
George Barr
Karl Barron
Adel Barry
Bartlett Cocke General Contractors
Michael Bartschat
Bath Fitter
Batteries Plus Bulbs
BayCare

Diane Baylor
BB&T
BBG of NKY
BCM One, Inc.
Be A Man Buy Land
Mr. Edmund Beebe
Belitway Cleaning Services
Bender Foundation, Inc.
Bender Insurance Solutions
Christopher Benrud
Michele and Howard Berger
The Bernal T. Chomeau Private Foundation
Bernard J and Camille Cebelak Foundation
Bernhard MCC
Paula Berry
Beta Engineering California LP
Laura and Steve Beuerlein
Deep Bharadwaj
BI Worldwide
Bill Thomas Associates, Inc.
Lisa Bilotti Foundation
Biotechnology Innovation Organization
Bird Road Subaru
George Bishop
BJ’s Restaurant Foundation, Inc.
Seth & Stacy Blackman Charitable Fund
Connie Blackmon
Aiden Blakemore
Angela Blank
Bloodworks NW
Blue Cross Blue Shield of Kansas City
Blue Marble Cocktails
Blue Water Financial Partners
Meredith Bluhm Wolf
BMC
Bob Rohrman Lexus of Arlington
Nancy Boeck
Alex Boggs
Janet and Logan Boggs
Boies Schiller & Flexner
Kelli and Don Bonacci
Nicolle Bond
Bootleggers’ Bash
Booz Allen Hamilton
Kate and David Borowski
Boston Biomedical
Boston Consulting Group
Boston Properties
Boston’s Best Coffee Roasters
Nichole and Todd Doro
Dorothy D. Smith Charitable Foundation
Doterra
Doug Schlegel Charitable Foundation
Dougherty Family Foundation
Doylesouth Health Cancer Institute
DPR Construction
Dr. Gerald and Paula McNichols Family Foundation
Tiffani Drake
Robin Driscoll
Drive Social Media
DRTDA
Dudley Family Foundation
Duff & Phelps, LLC
Duke Cancer Institute
Duke Family Foundation
Thomas Dunham
Dr. Thomas and Mrs. Barbara Dunham
Laura DuPont
Dorothea Durig
Dynasty Building Solutions
E. & J. Gallo Winery
The Earl and Brenda Shapiro Foundation
Janie Earng
Eastdil Secured, LLC
Deane Eastwood
Eston and Margaret Scripps fund of the Miramar Charitable Foundation
ECCE Select
Eckert Seams Cherin & Mellott, LLC
Ed & H Pillsbury Foundation
Ed Morse Automotive Group
Edith Stoner Foundation
Edrington Americas
Edward and Carol Miller Charitable Gift Fund
EGF Charitable Fund
EGF Charitable Fund c/o Isabel Welland
The Eli and Edythe Broad Foundation
Elite Development, Inc.
Elia B. Cleveland Trust
Elliott Davis
Sabrina and Scott Ellis
Elmwood Hospitality LLC
The Elpis Foundation
Kathleen and Bruce Elsey
Bob Emery
Endeavor Real Estate Group
Energy Alloys, LLC
Enterprise Holdings
EOG Resources
Epic
Epizyme
The Epstein Family
The Eric Scherbarth Leukemia Research Foundation
Ernest & Irene Pestana Charitable Foundation
Ernst & Young, LLP
The Escher Foundation
Estate of Joe Cattcart
Estates of Stoneridge Community, Inc., c/o Terrell & Amelia Gates
Gail Ewing
The Ethel and Harry Reckson Foundation, Inc.
EXIT Realty Corp. International
Exotek, Inc.
Express Scripts, Inc.
EY Philadelphia
Fareway Stores
Janet Faulkner
FD Stonewater
The Feighner Family Foundation
Edward Fein
Richard Fennell
FFC Investments of Raymond James
Fidelity Charitable
Findlay Automotive Group
First Data
First National Bank of Long Island
Marcus Fischer
Flatstick Pub, LLC
Mr. and Mrs. Jeff Floeck
Florida Crystals Corporation
Flushing Bank
FM Services Company
Foglia Family Foundation
Force 3, Inc.
Forgione Family Foundation
Foundation for Impact on Literacy and Learning, Inc.
Four Seasons Hospice
Fox 5
Fox Chase Cancer Center
Fox Corporation
Frampton Construction
Dianne Franco
Frank C. Diener Foundation
Frederick and Margaret L. Weyerhaeuser Foundation
Freeman Foundation, Inc.
Freepoint Commodities, LLC
Maurice Friedman
Roberta Frisch
Froedtert & The Medical College of Wisconsin
Fugus International
Tracye Funn
Vijaya Gadde
Gilles Gade
Maria Gaffney
Galen College of Nursing
Sameer Gandhi
T.H. Garner
Terrell Gates
John Gayle
David Gaynay
Gela, Wells & Mohr, Inc.
Gene and Jerry Jones Family Foundation
Leslie Geneen
General Dynamics Mission Systems
Gensler
Jim George
The George & Margaret McLane Foundation
George and Mary Josephine Hamman Foundation
The George F. And Myra Shaskan Foundation
The George & Margaret McLane Foundation
George L Shields Foundation, Inc.
The George Link Jr. Charitable Trust
GetWellNetwork, Inc.
Shiva Ghahremani
Saman Ghahremani, M.D. P.C.
Gilbane Building Company
Peter Gilbert
Gillman Subaru Southwest
Ginkel Family Fund
Steven Glaser
Lauren Glass
Global Payments Inc.
Global Traveler Magazine
Linda Glover
GM Financial
Rebecca Godchaux
William and Simone Godshall
Golfers vs. Leukemia
Gonsoulin Charitable Trust
Dr. Joseph Gonzalez
Good Samaritan Medical Center
Google
GovSmart
Grainger
The Grainger Foundation
Grane Rx
Great American Insurance
Greater Houston Community Foundation
Robert Greeley
Eric and Rachel Green
Greenberg Traurig
Greenstein Delorme & Luchs, P.C.
George Gresham
Terie Gresham
James Gresik
Greystar Development, LLC
Group1001
growth(period)
Gruenberg Kelly Della
David Grunenwald
GS Humane Corp.
Caroline Guerriere
Ronald Gula
Gwatney Buick GMC
Haley Garcia Group
Halliburton Foundation, Inc. (RM)
Kathleen Ham
Hamilton Casework Solutions
Ms. Suzy Hammond
Fred and Cherie Hand
The Handley Foundation
Audrey Hanken
Amy Hannah
Harder Mechanical
Price Harding
Ronald Hardy
Harkins Builders, Inc.
Janet and John Harper
Janet Harper
Mr. and Mrs. Christopher Harris
Harris Construction Co., Inc.
Harrisburg University of Science and Technology
Harry S. & Isabel C. Cameron Foundation
Donna Hartman
Bill Hartz
Harv’s Metro Car Wash
The Harvey E. Najim Family Foundation
Ray Haupt
Michael and Sophie Hayes
HCA Midwest and Sarah Cannon Cancer Institute
HealthCare Partners
HealthONE
Peter Hearne
Heartland Express
Randy and Nancy Hecht
Robin Heckenliability
Hedinger Family Foundation
Holly Heer
Bill Heer
Gayle and Jeff Helman
Helsinn Therapeutics, Inc.
John Hendley
Hendrick Subaru Southpoint
Henkels & McCoy
Wanetta Henry
Henry J Lee Distributors
Rich Heppe
The Heritage Group
Larry and Tammy Hershfield
Hewlett Packard Enterprise (HPE)
Donnie and Mary Franklin Foundation, Inc.
John Albuerne Family
John & Margo Simons Foundation
Doug and Kristen Johanson
Jewish Federation of Cleveland
Jerry’s Enterprises, Inc.
Jewish Federation of Greater Cleveland
Jim Koons Automotive Companies
Doug and Kristen Johanson
John and Mary Franklin Foundation, Inc.
John Moriarty & Associates of Florida
The John Newell Wade Foundation
Emery Johnson
Dan and Cindy Johnson
Johnson Operating Account
Jones & Frank
Jones Lang Lasalle Americas
Nelul Jose
Joseph Family Foundation
The Joseph R. Daly Foundation
Nancy Josephs
JRI Restaurant Holdings LLC
JS Capitol Group
Karen and Donald Jubel
Jude’s Gifts
Judge Technical Services Inc.
The Julius Family Foundation
The June and Cecil McDole Charitable Fund
K Machine Industrial Services
Gerald Kafka and Rita Cavanagh
Sandra and Stan Kahan
Ari and Genellie Kahan
Kaiser Orange County
Soumya Kalahasti
Andreas Kalisperis
Anne Kanelopoulos
Kasasa
Kayleen Larson Legacy Foundation
Mary Beth and Christopher Kearns
Keck Medicine of USC
Keeler Motor Car Company
Annie and Kevin Kelly
Kelly Floor LLC
Carrie Kemper
William and Diane Kenney
Daryl Kenningham
Kent Island American Legion Post No. 278
Richard and Gloria Kerns
The Kerr Foundation
Armen Khadiwala
Zahra Khaghani
Kieb Foundation
Susan Kilsby
King & Spalding
Kings Point Trust
Mr. and Mrs. Steve Kirby
Kirkland & Ellis
Emily and Neil Ksheter
David Klapfer
Kleinberg Electric
Kleinschmidt Family Foundation
KLS Public Strategies LLC
Koch’s Cares
Kolache Factory
The Kolter Signature Homes
Koppers Railroad Structures
Koppers Railroad Structures
Kevin Kordsmeier
Thomas Kornei
Bob and Jenny Kottler
Marc Kovar
Ray Kowalik
John Kriendler
Charles and Geraldine Kriser
Steven and Lisa Krikel
The Kroft Family Foundation
Dave Krosky
Labor Foundation for Union Workers
Laborers’ Local 190
Ladish Co. Foundation
Lake Family Foundation
Lalezarian Properties
Jay and Kelley Lamry
Hilaire Lanaux Jr.
Bob Lanphere Jr.
Latitude
The LaVerna Hahn Trust
Lisa Lawin
Ross Lawrence
Sheri Lawrence
Melanie Layer
Dr. Hillard M Lazarus*
Douglas Lebdab
Dean Leber
Dr. N. Ray Lee
Jeffrey Lefcourt
Lehigh Valley Health Network
Leon S. Peters Foundation
Leukemia 24/7
Don Levin
Levine Financial Group LLC
Lightning Community Hero
Linklaters LLP
Lion Group, Inc.
The Lipman Family
Michelle Little
Lois and Richard England Family Foundation
Houlihan Lokey
Long John Silver’s/A&W/KC
Mavericks
Suzanne and Albert Lord
The Lotz Family Foundation
Lou Fusz Subaru
Louisville Metro Government
Lowenstein Sandler LLP
Bruce Lowthers
Pike Electric
PJowa, LLC
Planet Fitness
Platformq Health, Inc.
Eileen and Gerald Poblocki
Kim and Nick Pomponi
Pondurance LLC
Scott Poole
Porsche North Scottsdale
Porsche of New Orleans
Porter Hedges LLP
Portland General Electric
Powell Industries
Praxair
Precision Biosciences, Inc.
Precision Lender
Press Ganey Associates
Mr. and Mrs. Jeff Preston
Mr. and Mrs. John W.S. Preston
Prometheus Partners
The Puente Family
Charline Pulizzi
Pure Storage
Quest Diagnostics
Quicken Loans
Quorum Software
R. G. Miller Engineers
The Rabbitt Whalen Family Foundation
Elizabeth Raleigh
Barbara Rapaport
Raymond James
Dorine Real and Lee Tepper
Real Estate One Foundation
Ms. Kimberly Reckley
RED Capital Group
Red River Technology
Jason and Heather Redpath
Regal Foundation
Regatta Network
The Reinalt-Thomas Corporation
Randy and Debbie Rehmnn
Andrea Reid
Adam Reinhardt
Mr. and Mrs. David Rendina
Mrs. Marjorie Rendina
Mr. and Mrs. Richard Rendina
Resilience Capital Partners
The Rhoda and David Chase Family Foundation, Inc.
Polly and Gregg Ribatt
Joe Ricciuti
Mr. and Mrs. Troy Rice
Richard M. Schulze Family Foundation
Rifenburg Construction
RMD Investors
Steve Robert
Robert J. Healy Elementary
The Robert R. Sprague Foundation
The Roberts Family
Roberts Oxygen Company, Inc.
Doug Robinson
Mr. and Mrs. John W. Robinson III
Gene Rochlin
Rock the Campus
Rockefeller Group
Rockland’s Greatest LTD
The Roderick Seward, Flossie Radcliffe and Helen M. Galloway Foundation, Inc.
Bonnie and Sam Roditti
Rotary Club of Nashua West
Rottendorf Pharma, Inc.
Mary Rowan
RSM
Keitha Russell
Roger Russell
Ruth Robinson
Jason Ryan
David Ryle
Robert & Barbara Sablowsky Foundation
Jeffrey and Catherine Sachs
Safeway
The Safeway Foundation
SailPoint Technologies
Salinas Valley Memorial Healthcare System
Niki Salter
Salzmann Hughes, P.C.
Sam J. Frankino Foundation
Sam’s Club
The Samek Law Firm
San Diego Sign Company
The San Francisco Foundation
San Jose Earthquakes
SAP Concur
SAP NS2
Sarah Tarditi Gallagher Memorial Golf Outing
John Saunders
Mr. and Mrs. Mark Saur
Savannah Chatham Imaging
Sawnee Electric Membership Foundation Inc.
Joel and Natalia Saxton
Anthony Scaramucci
The Schaufield Family Foundation
Scheid Family Wines
Laura Schlegel
Brian and Sandra Schneider
Schnucks Markets, Inc.
Schorr-Lieberman Family Foundation
Schumacher Construction Management, Inc.
Charles Schwab
Robert and Jennifer Schwing
Helena Scott
Scotts Valley High School
Scripps Green Hospital
SDS Restaurant Group LLC
The Segerstrom Foundation
Paul Seipp
Mark Seltzer
Servier Pharmaceuticals
Carl Sewell
Sewell Automotive Company
Seyfarth Shaw LLP
Samuel Shaheen
C. Kevin Shannahan
Sharp 471, Inc. dba / IHOP 471
John Shaw
Bill and Diane Shaw
Jere Shawver
Shepherd’s Chevrolet Buick GMC
Sherwood Forest SC
Douglas and Barbara Shindler
Matthew Shirah
Kevin Shivers
John and Marcia Shoooshan
Shopright Supermarket of Cherry Hill Inc.
R.L. Sias
Bart and Linda Sichel
Sidley Austin LLP
The Sidney, Milton and Leoma Simon Foundation
Sidney Kimmel Cancer Center at Thomas Jefferson University
Michael Siegel
Silicon Valley Community Foundation
Silver State Schools Credit Union
Mr. and Mrs. Robert Simmons
Simpot Food Group
Neal Simpson
Simpson Thacher
Dwight Sipprele
Sirus
Site Master
Skoda Contracting Co., Inc.
Charles and Meg Slater
The Sleep Family
Brad Smith
Douglas and Phyllis Smith
E. Smith
Jeff and Marnie Smith
Kristie Smith
Lester Smith
Mack Smith
Michael Smith
Michael L. Smith
William Smith
Hermine Soler
Sonic Automotive
Southeastern, Inc.
Southgate Glass
Southwest Local School District
Bonnie and Stephen Spiegle
Spire, Inc.
H. Mark Sponseller
Springfield Pancakes, Inc.
IHOP #4509
St. David’s Healthcare
St. Juste Management Corp.
Robert Stall
Gretchen Stangier
Star Anesthesia, PA
Statewide Restoration
Barb and Tom Stayton
Steel Dynamics Inc. & Keith Busse Enterprises
Kevin K. Steiner
Stemline Therapeutics
Jon Sterling
Jeffrey Stern
Steward Family Foundation
Stifel Financial
Mr. Kenny Stiles
Stritisa
Stoller Family Foundation
David Stone and Aileen Karstofsky
Kristin Stork
Strategic Education, Inc.
Strategic Site Development, LLC
David Gaynoe
Genevra Richardson’s Campaign Team
Simon George
Ben Gerber
Asaf German
Noora Ghahremani
Frank Giampoli
Scott Gildea
Gilman Lower School
Girls for the Green and Orange
Dylan and Zoey Glazer
Jay Glunt
Steven Goldstein
Stacy Goldstein
Amy Golladay
Frank Gordon
Gordon’s Groupies
Grace Toomey’s Campaign Team
Graci Graves’s Campaign Team
Alex Graf
Graci Graves
Maya Gray
Rick Gray
Adam Green
Green Tie Gaia / Chuck Cuda
Douglas Greene
Karen Gresham
Eric Grossman
William Gruver
Ashley Gulleidge
Ajay Gupta
Hala Ziady’s Campaign Team
Brad Hall
Summer Hall
Nancy Hamlin
Janet Ziegler Hanacek
Mark Hannah
Katie Hanshaw
Stephen Haraden
Carmen Harris
Denise Hartmann
Ashley Havera
Marianne Heatherly
Jill Heineck
Jamie Heidt
Kinsley Helmer
Jeff Helms
The Hene Dogs
Jessica Henderson - Funiestas
Nance and Heather Hendley
Abbie Hendry Hamnett
Hendry’s Heroes
Charlotte Henry
Herb’s Chain Gang Powered by Kailie’s Krew
Hikers4Life
Delaney Hill
Rachel Hines
Caleb Hinson
Thomas P. Hogerty and Team Blood Brother
Holden Beecher’s Campaign Team
Eli Holder
Eva Hooten
Robert Hope
Hopeful Hearts
Tim Houterloop
Kelli Howard
Tracy Howard
The Howard Hughes Corporation Constance Howlett
John Huber
Katye Huie Harrison
Morgan Hunt
Jonathan Hutton
Lindsay Iadeluca
Clayton Idile
Renjitha Ignatius
In honor of all who have battled Hodgkin’s Lymphoma (Chris Saizan)
In honor of Bill Fores (Team 209)
In honor of Caleb McNitt (Ride For Dads)
In honor of Cassidy Sidhu and in Memory of Lou Cole (Thea Campbell)
In honor of Firas Nassif (Taro Arai, Mikuni Charitable Organization)
In honor of Frank Amaral (Team 209)
In honor of Garrett Heisinger (Team Courageous)
In honor of Lisa Villamil (Team Living Victoriously)
In honor of Mike Tooley (Team Tooley)
In honor of Omar Ali (Abdul Ali)
In honor of Ryan Tooley (Team Tooley)
In honor of Team Don’t Stop Believing (Firas Nassif)
In memory of Bernice N. Zahn (Melvin Bradley)
In memory of Dennis Bravo (Team 209)
In memory of Irene Christopoulos and Donald Procida (Marisa Christopoulos)
In memory of Joe Fitzgerald (Kate Fitzgerald)
In memory of Rami Zakhour (Firas Nassif)
Joe Innacone
InvinciBill
Jack Maine’s Campaign Team
Trent Jackson
Ava Jambor and Noah’s Army
Denisse James
Janine Ward’s Campaign Team
Bryan Jansen
Jason Smith’s Campaign Team
Jeffrey Rovner’s Campaign Team
Jen Thomas’s Campaign Team
Jennifer Brown’s Campaign Team
Jeremy Schwibrner’s Campaign Team
Jerni 4 a Cure
Jan Jernigan
Jessica Burgess’s Campaign Team
Jessica Henderson - Funiestas’s Campaign Team
Jhansi Koduri’s Campaign Team
Jim Kaufman’s Campaign Team
Wendy Jirs
Joe Maio’s Campaign Team
John Huber’s Campaign Team
John McDonough’s Campaign Team
Jhonny Mercado’s Campaign Team
Nora Johnsmeyer
Andrea Johnson
Bert Johnson
Tracy Johnson
Andrew Jones and Team Live Life Stronger
Chris Jones
Lauren Jones
Jonestin’ for the Cure
Julie Buschman’s Campaign Team
Julie McPherson’s Campaign Team
Just Cure It – CTWHV
Just Cure It – Illinois
Just Cure It – NYC
Just Cure It! – Long Island
Just Cure It! – PHX
Just Peachy
Lilly Kannapeil
Katherine Thornhill’s Campaign Team
Kathy Pidgeon’s Campaign Team
John Katsetos
Michael Katsock
Peter Katz
Jim Kaufman
Micaela Keane
Keane on Beating Cancer
Ken Schwing’s Campaign Team
Jennifer Kennedy
Brett Kessler
Eric Kesti
Amen Khadiwala
Aamilah Khanu
Kick Leukemia’s Zaas
Kate Kilroy
Parker Knk
Chuck Kiven
Kiven, Kotler, Lieberman, Fox, Goldschmidt, Kepes & Lev
Lance Knez
Knockout Blood Cancer
Jhansi Koduri, M.D.
Stanley Koehl
Matthew Koff
Koppers
Lee Korn
Bob and Jenny Kottler
KPMG Cycle
Kristen Krikorian
Kristen Meyer’s Campaign Team
Kristie Welte’s Campaign Team
Dave Kuba and Team Reality Fights
Jessica Kuba
Michelle Kuhn
J. Marc Kurowski
Max Landwith
Lanphere Auto Group
Blair Larkins-Seyfried
Larry Treen Jr.’s Campaign Team
Lauren Esposito’s Campaign Team
Lauren Riggs’s Campaign Team
Lauren Simione’s Campaign Team
Emily LeBlanc
Katherine Lee
Dr. N. Ray Lee
Chad Lefteris
Lehigh Valley Circle of Hope
Elizabeth Lehr
Leslie Coxon’s Campaign Team
Tyler H. Lester
Alanna Levine
Alexa Levine
Valerie Lewis
Nadine Link
Tracy Link
Loree Lipstein
Michelle Little
Lynn Liu
Bernard Llave
Brittany Lofton
Loree Lipstein's Campaign Team
Christie Ludwig
Sauris Lugo
Lymphomaniacs
Lynn Aronberg's Campaign Team
Logan Maciejewski
George Macon
Mad Lion
Dr. Michael Magoon
Jack Maine
Joe Maio
Iman Malhi and Nyari Muchaka
Manuela Yanez's Campaign Team
Marc Kurowski's Campaign Team
Jaiyn Marcel
Megan Maroneyak
Margo's Marathon Maniacs
Marianne Heatherly's Campaign Team
Mario DeFrancesco III's Campaign Team
Richard Marquez
Sidney Marsh
Brian Martinenza
Jany Martinez-Ward
Anthony Maslow
Valerie Maslow
Colton Matter
Max Landwirth and Team #FromTheHeart
Mayhul Patel's Campaign Team
Kathy Mazzei
Drew and Shelley McCandless
Katey McCandless
Mackenzie McCarter
John McDonough
Dana McGinley
Miles McIlvaine
Gibson McKay
Bill McKenzie
Hannah McNeal
Julie McPherson
Megan Freas’s Campaign Team
Kimberly Meincke Jacobsen
Forest Melton
Heath Melton
Jhonny Mercado
Laurie Merrick
Kristen Meyer
Michael Magoon’s Campaign Team
Michael Rottio’s Campaign Team
Michelle Little’s Campaign Team
Michelle Ralph’s Campaign Team
Jackie Milla
Derek Miller
Jack Miller
Sydney Miller
Miller’s Rogue Fishers
Miracle Makers
Miracle Maya
Mission is Possible
Camille Miura
Matt Mobley
Xavier Monper
Meghan Monahan
Amanda Montell and The Lymphomaniacs
Isabella Montero
Jen Moog and Team #gameon
Antonio Moore
Ryan Morris
Kevin Morris
Stacey Moser
Jake Mouton
Kelly Munyan
Patrick Murphy
Bridget Murray
MWOLYLA Leadership Committee’s Campaign Team
My Girl
Drew Naiburg-Smith
Nathan Stallings’s Campaign Team
Geri Naumberg
Jim Newman, CPA
Natalie Noss Handler
Lindsey Noto
NYC Alumni & Friends
Chris O’Brien
Greg Oldham
Camille Olivere
Scott Olmsted
Elie Olshanski and Team Make a Difference
On Board for a Cure
Scott Paris
Parker Kink’s Campaign Team
Teeny Parks
Alyssa Parrish- Bublewicz
Kritesh Patel
Sachit Patel, MD
Sara Patterson
Sarah Paul
Peel’s Pirates
Peter Katz’s Campaign Team
Petes Posse
Kathryn Pidgeon
Dr. Bud Pierce
Scott Pioneck
Erica Pizzeck
Jenny Pleasant
Plymouth Elementary School
Pop’s Warriors
Reese Power
Libby Powers
Lauren Prenaveau
Abby Price
Demitrius Puente
Christine Pullara
The Purple Pride Saves Lives
PwC - NYC
Aimee M. Quirk
Leena Rai
Raise for a Cure
Rampart High School
Kevin Raymond
Ryan Reilly
Tara Reilly
Relentless Raiders
Sarah Reuter
Susan Rheingold
Geneva Richardson
Eloise Richter
Riders Of The Storm
Will Rigby
Lauren Rigg
Carson Riley
Michael Rottio
Kenzie Robertson
Robin Thurau’s Campaign Team
Annie Rose Robinson
Mackenzie Robinson
Renee Robinson
Rick Roby
Rockin’ Out Cancer
Will Rogers
Philip Roman and Jarrod Gans
John Romley
Sondra Rose
Steven Rosen
Bob Roth
Caroline Roth
Jeffrey Rovner
Heath Rudduck
RumFront
Gabrielle Russo
Daniel Ryan
Ryan Cohen’s Campaign Team
Ryan Morris’s Campaign Team
Will Sabayarac
Sachit Patel, MD’s Campaign Team
Jon Sadler
Sahm Cho’s Campaign Team
Adria Salas
Salesforce
Salesforce.com-“Boston Strong”
Erika Salinas
Neil Salvage
Salvatore R Calabro
Elementary School
Tori Santos
Sarah Paul’s Campaign Team
Sarah Shirley Smackdown
Kimberley Sason
James Saviar
Jake Schillt
Tommy Schroeder and Team FireFight Cancer
Schuyler Colfax Middle School
Martin Schweitzer
Ken Schwing
Helena Scott
Scott Bores’s Campaign Team
Scott Paris’s Campaign Team
Liz Szcudlo
SDG&E/Sempra
Seattle Genetics
Kevin Shannahah
Allison Shapiro Dandry
Mark Shay
Stacie Sheely
Kevin Shivers
Sophie Shumway
Lauren Simione
Sisters By Blood
Callie Skurla
Smiles for Miles
Elizabeth Smiley and Team Smiley
Holden Smith
Kyle Smith
Jason Smith
Serena Smith
Jared Smukler
Sophia and Margot’s Survivors
Kari Souers
Jonathan Spaeth
Dara Spearman
Allyson Spring
Troy Springer and Cinzia Rolling
Stacie Sheely's Campaign Team
Stacy Goldstein's Campaign Team
Nathan Stallings
Dean Stamoulis
Stanley Koehl's Campaign Team
Stacie Sheely's Campaign Team
Nathan Stallings
Dean Stamoulis
Stanley Koehl's Campaign Team
Nick Starr
Stater Bros. Markets
Kevin Steckley
Donald and Margaret Steiner
Sullie Stephens
Kate Stevens
Anna Stewart
Brad Stinson
Raul Storey-Rojas
Justin Stout
Abigail Stoy
Stratford School at Osgood
Stephen Strickland
Saunder Strong
Heather Stubblefield
Daniel Sullivan
Katie Sullivan Taulane
Vonnie Sullivan
Summer Hall's Campaign Team
Susan Rheingold's Campaign Team
Skylar Takac
Scott Takanen
Mona Talukdar
Tammy Motley's Campaign Team
Wine Tasting
Mark Taylor
Team EMI
Team Alaska Airlines
Team All Stars
Team Art
Team b. strong
Team Baja
Team Beat 41 - Lily Johnson
Team Beeches Beat Cancer
Team Blumenfeld-Waterman
Team Bucket List Cure Cancer
Team Chemo Sabe
Team Chrisman
Team Coast to Coast
Team Crushers
Team CUREageous
Team Cure-aLLS
Team Deconstructing Cancer
Team DeFREEzing Cancer
Team D.R.E.A.M
Team Droplet Like It's Hot
Team Fearless Dragons
Team Fight Cancer
Team Fire Hearts
Team Go Gold
Team Gordo's Groupies
Team Hamlin's Cure-saders
Team Heart Roots
Team Hero - Luke Hattfield
Team Ho'omau
Team Hope
Team Hudson
Team Husky
Team Hutton 1045
Team Jim Thorpe
Team JumpingForJoy
Team Justin
Team Leticia Juarez in Memory of Pamela Johnston
Team Live Love and Adventure - Patty Leehmuis
Team Lori
Team Lymph-busters
Team Maddie's Mission
Team Mighty
Team NARS
Team Nike
Team Panthers Against Cancer
Team Phoenix
Team PwC: Run for Richard
Team Reid
Team Scream Survivor
Team Soulunimation
Team Stanley
TEAM SURVIVOR
Team Teeny for the Cure
Team Tobon
Team Turn Up For The Cure
Team Victory Royale
Team Ward Law Group
Team Wendy's
Team Wishes for a Cure - Heather Hibbard
Team Wishful Workers - Jennifer Oz
Team Worth the Fight
Team Zephyr
Terumo BCT
The Three MuskeCUREs
The Tiger Stripes
Nichole Theriault
Andy Thieman
Kate Thomas
Kennedy Thomason
Robin Thurau
Tim Houterloot's Campaign Team
TNT Caballeros
Tocqueville Asset Management
Megan Toner
Grace Toomey
Brianna Torgerson
Tour 2 Cure
Cara Tovissi
Matt Tovrog
Chris Townsend
Tracy Johnson’s Campaign Team
Larry W. Treen Jr.
Yvette Tremonti
Trent Jackson’s Campaign Team
Annie Trimberger
Trividia Health, Inc.
Dominic Tully
Turkey Shoot Golf Tournament
Twiggy's Dream Team
Bryce Unger
Grace Unger
Sohan Upadhya
Lauren Valentine
Valerie Lewis’s Campaign Team
VALiant Warriors
Brent VanLoo
Nicholas Van Zandt
Julia Vasco
Mr. and Mrs. Leo Vecellio
Carmen Vega
Anthony Velardi
Zarmeena Vendal, MD
Banner Vicary
Victoria Santos's Campaign Team
Lindy Monforte
Yvette Tremonti’s Campaign Team
Jake Zaas
Hala Ziad
Claire Ziegler
Bella Zinkin and Sienna Saxton
Washington Gas - 10th Annual Golf Tournament
Katie Waters
Watertown Middle School
The Wawa Foundation
Weddington Middle School
Weiler Foundation
Greg Weimer
Kristie Welte
West Ridge Middle School
Whaboom
When Pigs Fly: Making the Impossible Possible
Jenna Whitehead
Nancy Whitman
Jessie Wiener
Wilkes & McHugh
Will Rigby’s Campaign Team
Will Rogers’s Campaign Team
William Mason High School
Rob Williams
Dwayne Wilson
JP Witkop
Wolfpack (Hunting For A Cure)
Stephanie Wong
World of Warriors
Jillian Wright
Randy Witz
Manuela Yanez
Preston Yorx
Matthew Yost
Yvette Tremonti’s Campaign Team
Jake Zaas
Hala Ziad
Claire Ziegler
Bella Zinkin and Sienna Saxton
Legacy Circle

Legacy Circle honors those who designate LLS as a beneficiary of their will, trust, retirement account or insurance policy, or fund a charitable gift annuity. We list our newest members below along with those whose bequests of $10,000 or more were received this year:

Edward Darden Baines*
Michelle Bargeron*
Alice Ann Bien*
Joyce Boice*
Margaret and John Bruner*
William P. Caloccia*
Kalpana Chakraburty in memory of Shib Chakrabarty
Roseann Comstock*
Alan Cook*
Gregory D’Angelo in memory of Diane D’Angelo
Robert DeVolder*
Nicholas Dissler*
Peggy and Margaret Dupaquier*
Robert Ellis*
Judith Erickson*
Anita Foster*
Grace Fram*
Barbara Frattura* in memory of Pasquale (Pat) R. Frattura
Nancy Hall*
Victoria Harris*
Ferris Hartman*
Susanne Hassell*
Alice Hejl*
Barbara Helman*
Rowena Huddle*
Lewis Kaplan*
George Keleher*
John Kellenyi**
Wayne Kenfield*
James Kimble*
Else Korb*
Legion Kramer*
Martha Lacy in memory of William R. Lacy
Albert Lee
Sanford Levinson in memory of Elaine Levinson
Howard Bruce Linden in memory of Walter William Linden
Debra Linck
Margaret MacMurray*
Ronald Marony*
Elaine Meyers-Matloff*
Emily Papapietro*
Mary Alice Parks*
Mary Perluss*
Renee Pittin*
Gretchen Pressburg
Eugene Regener, III*
Michael Rinaldi*
Gene Rochlin*
Sally Rossiter*
Gail Secrist*
Bruno and Irma Seimi*
Roselle Shaw*
DJ Smith-Brooks*
Robert Snincak*
Wanda Starkey*
Jo Ann Taylor*
Mitchell Tobin and Susan Jacobson in memory of Nancy Tobin

Endowment Funds

The Bill Beattie Memorial Endowment Fund (Alberta)
de Villiers Endowment Fund
GlaxoSmithKline Foundation
- Gertrude B. Elion Endowment Fund
GlaxoSmithKline, Inc. Research Fund

Jane Elissa/Charlotte Meyers Endowment Fund
Jim Jacobs Leukemia Research Fund
Mary & Robert Bronstein Memorial Fund

The Rachel Kudish Fund
The Rae Endowment Fund (Ontario)
Reich Endowment Fund
Thomas M. Ford Memorial Fund
The United Food and Commercial Workers (Canada) Endowment Fund

The Virginia Major Brooks Memorial Endowment Fund
Vrushali Ranadive Fellowship Fund

* Deceased
† We proudly recognize John Kellenyi, generous, longtime supporter and Beat AML Campaign co-chair, for his leadership, compassion, and commitment
Research Portfolios

LLS Research Portfolios are groups of research projects organized around a specific blood cancer interest. The list below includes donors that generously invested in a specific LLS research portfolio during this fiscal year.


Patient Support & Public Policy Portfolio is funded in part by Allegheny Foundation, The John and Frances Beck Family Foundation, UCLA Kaiser Permanente Center of Health Equity, and anonymous.


Acute Lymphoblastic Leukemia Research Portfolio is funded in part by Lisa Norcia Cheskin and Barry Cheskin and the Eric Scherbarth Leukemia Research Foundation, Inc.

Chronic Lymphocytic Leukemia Research Portfolio is funded in part by Alex Boggs, Steven and Sandy Brannon, and Sharon and Paul Dillon.

Chronic Myelogenous Leukemia Research Portfolio is funded in part by Leslie and Larry Nance.

Hodgkin Lymphoma Research Portfolio is funded in part by AM Charity Fund and Terry D. and Carol A. Agness Charitable Trust.


Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by Donna Hartman, and Rochelle Klutch.

Immunotherapy Portfolio is funded in part by The Alice Lawrence Foundation, Inc. and Janet Faulkner.

Information Resource Center (IRC) is funded in part by Adel Barry.

Lymphoma Diagnostics Program is funded in part by Chiyoko Furukawa.

Therapy Acceleration Program is funded in part by Robert and Nancy Rosen, Lois and Jerry Rosenblum, and Allen Zachary.

The Susan Lang Pay-It-Forward Transportation Assistance Program is funded in part by The Grainger Foundation, Lang / Stiglitz Family Fund, and anonymous.


Precision Medicine Initiative is funded in part by The Harry T. Mangurian Jr. Foundation, Inc.
Leadership

National Board
Volunteers serve on our National Board of Directors providing leadership and governance to help find blood cancer cures.

Officers

Chairman of the Board
Jorge Benitez
Fort Lauderdale, FL

Vice Chair
Bart Sichel
Bucks County, NJ

Secretary/Treasurer
Ralph E. Lawson, FHFMA, CPA
Parkland, FL

At Large
Kathleen Meriwether
Ernst & Young, LLP
Philadelphia, PA

Directors

William G. Behnke
The Behnke Group
San Antonio, TX

Peter Brock
Brock Development
Palm Beach Gardens, FL

A. Dana Callow, Jr.
Boston Millennia Partners
Boston, MA

Renzo Canetta, MD
Madison, CT

Casey Cunningham, MD.
Sante Ventures
Houston, TX

William S. Dalton, MD, PhD
2Gen
Tampa, FL

Samuel Eberts, III
Chapel Hill, NC

Christopher Flowers, MD
Emory University
Atlanta, GA

Janice Gabrilove, MD.
Icahn School of Medicine
at Mt. Sinai
New York, NY

Bernard H. Garil
Delray Beach, FL

John Greene
Salesforce
San Francisco, CA

Francie Heller
Arabesque Asset Management
New York, NY

Michelle LeBeau, PhD
University of Chicago
Comprehensive Cancer Center
Chicago, IL

Connie L. Lindsey
Northern Trust
Chicago, IL

Ruben Mesa, MD
Mays Cancer Center
San Antonio, TX

Ted Moroz
The Beer Store Ontario
Toronto, ON, Canada

Harry Moseley
Zoom
San Jose, CA

Lynne O’Brien
McLean, VA

Maria Persky, JD
WOMN LLC
Ridgfield, CT

Donald Proctor
Bk97 Digital
Walnut Creek, CA

Robert Rosen
Greyhawk Capital Advisors LLC
West Palm Beach, FL

Steven T. Rosen, MD, FACP
City of Hope
Duarte, CA

Jeff Sachs
Jones Lang LaSalle
Duluth, GA

Kenneth Schwartz
Ernst & Young, LLP
New York, NY

Keith S. White
ParkerWhite Brand Interactive
Cardiff by the Sea, CA

Executive Leadership

The Leukemia & Lymphoma Society

Louis J. DeGennaro, PhD
President & Chief Executive Officer

Danielle Gee
Chief of Staff

Kathy Griesenbeck
Executive Vice President
Chief Relationship Officer

Marcie Klein
Executive Vice President
Chief Communications Officer

The Leukemia & Lymphoma Society of Canada

Alicia Talarico
President
Canadian Operations

Offices

United States:
https://www.lls.org/
chapter-selection-page

Canada:
http://www.llscanada.org/
chapter-selection-page
The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. Find out more at www.LLS.org.